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ABSTRACT 
 
Anna Barry Cope: Assessment of HIV transmission and diagnosis patterns in North Carolina 
(Under the direction of William C. Miller) 
Diagnosis, presentation to care, and initiation of antiretroviral therapy during the early 
stages of HIV have substantial individual and public health benefits. However, current estimates 
of the HIV care continuum, or care cascade, indicate that most HIV-infected persons in the US 
are diagnosed late in the course of their disease and even more do not achieve viral suppression. 
The purpose of this dissertation was to characterize the cascade-related behaviors of persons 
participating in active transmission networks and examine the geographic barriers to early 
diagnosis. Using data collected as part of the North Carolina (NC) Screening and Tracing of 
Active Transmission Program, we assessed the HIV status and if HIV-infected, the diagnosis, 
care, treatment and viral suppression status of named partners of persons acutely-infected with 
HIV (index AHI case) between 2002 and 2013. More than one-third of all traceable partners 
were HIV-infected. Most observed transmission events appeared attributable to previously-
diagnosed partners (77.4%, 95% confidence interval 69.4-85.3%), of whom only 23.2% (14.0-
32.3%) were in care and on treatment near the index AHI case diagnosis. Among 
phylogenetically-linked cases and partners, 60.6% of partners were previously diagnosed (43.9-
77.3%).  
iv 
 
Using HIV surveillance data from a 52-county region in central NC, we mapped new 
diagnosis rates by stage of disease (early, chronic, and AIDS) and testing period (2005-2007, 
2008-2010, 2011-2013). Maps were standardized and the percent overlap of high rate diagnoses 
(top 10
th
, 25
th
 and 50
th
 percentile) by disease stage and testing period were assessed. We 
identified a definite, underlying core area of HIV as represented by disproportionately high 
overlap in the top 25
th
 and 50
th
 percentiles by disease stage and testing period. The identification 
of early infection varied geographically over time, suggesting changes in testing behaviors or the 
epidemic itself. Relatively high rates of AIDS diagnoses persisted over time in the southeastern 
part of the study area. Finally, we assessed the association of distance to a publicly-funded 
testing site with stage of disease at diagnosis. Traveling longer distances to the testing site of 
diagnosis, particularly when a closer testing site was available, increased the prevalence of post-
early stage diagnoses (prevalence ratio=1.09, 1.03-1.16).  
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For the people of North Carolina living with HIV 
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CHAPTER ONE: SPECIFIC AIMS 
Diagnosis, presentation to care, and treatment during the early stages of HIV have 
substantial individual and public health benefits.
1-6
 Antiretroviral therapy (ART) results in 
dramatically higher life expectancies and lowers the probability of HIV acquisition in uninfected 
sexual partners.
1,6,7
 These benefits require early HIV diagnosis, followed by entry into and 
continued engagement in HIV care. This series of steps has been formalized into a framework 
commonly referred to as the “HIV treatment cascade.”8  
Losses along the HIV treatment cascade represent substantial numbers of missed 
opportunities to optimize health and limit HIV transmission.
8,9
 Efforts have been made to 
estimate the number of HIV-infected persons in each stage.
8
 However, the contribution of each 
stage on HIV transmission depends not only on its size, but also on the behaviors and 
infectiousness of persons in the stage. Current models indicate that persons unaware of their HIV 
infection account for the majority of transmission.
10,11
 Geographic barriers, including rurality and 
distance, often exacerbate delays in diagnosis, impacting morbidity and transmission.
12,13
 
However, the transition to opt-out testing in 2007 may have had implications on when HIV-
infected people test in the US.
14
 Empirical estimates of the contribution of each stage of the 
cascade to transmission can improve the accuracy of transmission models, while a more 
developed understanding of the geographic barriers to early diagnosis allow for effective 
targeting of limited HIV prevention resources.
15
  
The HIV treatment cascade provides a useful framework for assessing the potential
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impact of the HIV testing and care system on transmission. Unlike many other states, the North 
Carolina (NC) Division of Public Health (DPH) has the capacity to classify stage of disease in all 
new HIV diagnoses. The NC DPH maintains demographic and clinical data on all persons 
diagnosed with HIV or AIDS in NC in eHARS (electronic HIV/AIDS Reporting System).
16
 
Recent HIV diagnoses (cases identified within 6 months of infection) have been estimated 
through the serologic testing algorithm for recent HIV seroconversion (STARHS) assessment 
since 2005.
17,18
 Persons diagnosed with acute HIV (AHI) and their sexual and needle-sharing 
partners are tracked via the Screening and Tracing of Active Transmission (STAT) program.
16
 
Taken together, data from these surveillance systems provide a unique opportunity to explore the 
diagnosis, care, and treatment status of HIV-infected persons in active transmission networks and 
assess the contribution of geographic location to delays in diagnosis and possible HIV 
transmission. This assessment can direct future resources for HIV testing and care towards 
persons at greatest risk for acquiring and transmitting HIV. Specifically, we aim to:  
AIM 1: Estimate the relative contributions of persons with AHI, previously undiagnosed 
established infection, and diagnosed established infection (in care vs. out of care, treated vs. 
untreated, virally suppressed vs unsuppressed) to ongoing transmission in NC. 
Hypothesis: We hypothesize that the majority of suspected transmitting partners will be unaware 
of their disease status.  
Overview: We will use disease intervention specialist (DIS) interviews of persons with AHI to 
identify reported sexual and needle-sharing contacts that have been cross-matched in 
surveillance databases to allow identification of their HIV status, and for HIV-infected contacts, 
their diagnosis (newly- or previously-diagnosed), care, treatment and viral suppression status. 
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These data about the sources of incident HIV infection will provide preliminary information 
about the transmission contributions of people in each cascade stage. 
AIM 2: Assess spatial clustering and patterns of HIV diagnoses by stage of disease both before 
and after opt-out HIV testing was implemented in NC.   
Hypothesis: We hypothesize that acutely and recently diagnosed persons will cluster near urban 
centers in NC, while persons diagnosed with chronic HIV and AIDS will display a more 
dispersed spatial pattern. 
Overview: We will aggregate all newly diagnosed persons coming out of publicly-funded testing 
sites in central NC between 2005 and 2012 at the census tract level.  Stage of disease will be 
determined by data provided by the STAT program, HIV Incidence Surveillance project, and 
eHARS. Bayesian Maximum Entropy (BME) and SaTScan will be used to evaluate differences 
in clustering by stage of disease at diagnosis over the entire time period, as well as before (2005-
2008) and after (2008-2010 and 2011-2013) the implementation of routine, opt-out testing.  
AIM 3: Examine the relationship between stage of disease at diagnosis and proximity to both the 
closest publicly-funded testing site as well as the testing site where diagnosed with HIV.  
Hypothesis: We hypothesize that cases diagnosed with chronic disease or AIDS will live farther 
away from publicly-funded testing sites than cases diagnosed with acute or recent HIV.       
Overview: For all patients identified in Aim 1, we will use log-binomial regression models that 
account for clustering at the neighborhood level to assess the effect of geographic distance from 
both 1) the actual site of diagnosis and 2) the closest publicly funded testing site to the case’s 
address on the stage of disease at diagnosis.  
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CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
Epidemiology of HIV/AIDS in the Southern United States 
In the United States, the 16 states plus the District of Columbia that make up the 
American South experience a disproportionate burden of HIV morbidity and mortality in the 
United States (US). The South accounted for 46% of all new HIV infections, while only 
representing 37% of the population in 2010.
19
 The estimated proportion of AIDS diagnoses in 
the South increased from the third highest percentage in 1981 (15.8%) to the highest percentage 
in 2010 (44.6%).
19,20
 While still comparatively high, recent trends indicate a slight decrease in 
both the number of persons living with HIV and the rate of new diagnoses between 2007 and 
2010 in the South.
19
  
The elevated level of HIV-related morbidity in the South is due to a multitude of factors 
related to demographics, economics, and infrastructure. As compared to the rest of the country, 
this region is comprised of a higher percentage of Black persons and a greater concentration of 
persons living in poverty areas (defined by the US Census Bureau as a census tract with poverty 
rates of 20% or more). Additionally, the South is markedly less urban in nature, with more than 
40% of the population living outside of an urban area, versus 30.8% in the rest of the US.
21
 
The regional burden of disease in the US is largely consistent with the demographic 
distribution of the population,
19
 with HIV primarily concentrated in ethnic minorities in the
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South.
22,23
 The highest rates of HIV are among black persons (57.2%), women (23.8%), and 
those reporting heterosexual risk (15.0% for males and 88.5% for females).
19
 Persons living with 
HIV and reside in a rural or suburban areas is disproportionately high in the South.
19
  
As observed in other parts of the US, the South is currently experiencing increases in 
both the rate and number of new HIV diagnoses among young men between the ages of 13 and 
29 years.
18,19
 Men who have sex with men (MSM) are also disproportionately affected by 
HIV/AIDS in the South; only 34% of self-reported MSM lived in the South in 2007,
24
 but 43% 
of AIDS cases in MSM live in the region.
25
 The South was the only region in the US where black 
MSM living with HIV outnumbered white MSM.
26
 High rates of sexually transmitted infections 
(STIs) and the presence of concurrent partnerships in affected populations in the South increase 
the likelihood of HIV acquisition and transmission in this region.
27,28
 
Persons living in the South experience worse outcomes after an HIV diagnosis compared 
to other regions. Southerners have higher case-fatality rates
29
 and experience poorer 36-month 
survival rates.
19
 Persons living in the South have a higher likelihood of experiencing HIV-related 
morbidity as compared to persons residing in other parts of the country, particularly among non-
whites.
30
 These poor outcomes have been linked to problems with access to HIV testing and care 
that are exacerbated by a history of distrust in the health care system, inadequate HIV and STI 
care infrastructure, distance to care services, and stigma surrounding HIV.
31-34
 
The Epidemiology of HIV in North Carolina: Approximately 1500 new cases of HIV are 
diagnosed annually in North Carolina (NC). The absolute number of new HIV diagnoses has 
decreased since a peak in 2008. In 2009, NC was ranked 8th in terms of new HIV diagnoses in 
the US, with a rate of 23.8 per 100,000 which was slightly higher than the national average of 
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21.1 per 100,000. Trends observed over the entire region classified as the American South are 
similar to those seen in NC, where HIV is disproportionately represented among minorities and 
the economically disadvantaged. The 2010 rate of new HIV diagnoses for blacks (59.7 per 
100,000) was more than nine times greater than that of whites (6.5 per 100,000). The diagnosis 
rate for Hispanics was almost four times higher than that of whites. The male-to-female ratio of 
new diagnoses has risen from 2.5 in 2006 to 3.2 in 2010.  In males, 75% of the new diagnoses 
were attributed to MSM risk behaviors in 2010. That same year, in females, heterosexual sex 
accounted for 95% of HIV diagnoses. Urban areas account for the majority of HIV prevalence in 
NC, with over 50% of new HIV cases being diagnosed in 5 of NC’s 100 counties (Mecklenburg, 
Wake, Durham, Guilford, and Cumberland). In 2006, the CDC reported that NC had the highest 
number of reported cases in rural areas for both AIDS and HIV in the US.
16
 
The HIV Treatment Cascade 
Antiretroviral therapy (ART) has led to dramatic improvements in HIV-related morbidity 
and mortality. Test-and-treat strategies for HIV prevention suggest that expanded testing and 
earlier treatment of HIV has the potential to significantly decrease ongoing HIV transmission, 
and therefore limit the HIV epidemic.
35
 A test-and-treat strategy cannot be effective without 
stressing the importance of linkage and retention in care. Successful establishment of HIV 
treatment requires that a diagnosis of HIV is followed by timely linkage to care, prompt initiation 
of ART, and subsequent adherence to prescribed medications. In July 2010, the U.S. National 
HIV/AIDS Strategy set as one of its main priorities to increase access to care and improve health 
outcomes for people living with HIV/AIDS.
36
 To fully benefit from ART, patients must progress 
through the HIV Treatment Cascade [Figure 2.1] while remaining engaged in uninterrupted HIV 
clinical care.
3,8,37-39
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Unrecognized HIV Infection: In the US, approximately 20% of HIV-infected persons are 
unaware of their disease status.
40
 These persons cannot engage in HIV care and treatment, tend 
to participate in riskier behaviors, and may have a higher risk contributing to ongoing 
transmission of disease.
10,11,40-42
 Mathematical models have estimated that between 50-70% of all 
new infections are attributable to people who are unaware of their HIV serostatus.
10,11,43
 These 
models are based on a combination of empirical data and difficult-to-verify assumptions when 
empirical data was unavailable.
10,11,43
 Additional empirically collected data about the care and 
treatment status and risk behaviors of the transmitting partners could improve the validity of 
these estimates. 
Among the persons newly diagnosed with HIV infection in the US, 35%-45% have AIDS 
within 1 year after diagnosis.
8
 In 2010, 49% of all AIDS diagnoses in NC were made at the same 
time or within six months of their HIV diagnosis.
16
 Late-stage diagnoses are generally more 
common among persons who are not perceived or who do not perceive themselves to be at high 
risk for infection, among those not actively offered HIV testing, and among marginalized 
groups
44
 In a 2003 report, persons tested late in the course of their disease were more likely to be 
black or Hispanic and to have been exposed through heterosexual contact.
9
 These results 
prompted the Centers for Disease Control (CDC) to launch the “Advancing HIV Prevention 
Initiative” in 2003, whereby simpler testing procedures were adopted.  Pretest counseling was 
eliminated and testing recommendations were expanded to persons with risk factors in low 
prevalence settings.
45
 This initiative was followed by further recommendations in late 2006 to 
adopt routine, voluntary HIV screening for patients in all health care settings. The 2006 
recommendations aimed to enhance earlier detection of HIV infection, identify and counsel 
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persons with unrecognized HIV infection and link them to clinical and prevention services, and 
continue to reduce perinatal HIV transmission.
14
 
Many healthcare professionals have endorsed routine HIV testing in all healthcare 
settings as a way to de-stigmatize the testing process and facilitate access to clinical care for 
newly diagnosed persons
14,46-48
 Additionally, streamlining the HIV testing process may make it 
easier for health care providers to conduct HIV testing.
49
 Approximately 54% of U.S. adults, 
aged 18 to 64, have reported ever being tested for HIV, including 21% who reported being tested 
within the past year.
22
 Critics of the CDC’s 2006 recommendations are concerned that the non-
targeted HIV-screening policy might involve inefficient over-testing of low risk populations. The 
results of mathematical modeling evaluations of the cost-effectiveness of these recommendations 
in the general population are mixed.
50-52
 
Delays in Presentation for Medical Care: Delays in linkage to HIV medical care are associated 
with greater likelihood of progression to AIDS and increased risk of transmission.
4
 Between 
69%-90% of persons diagnosed with HIV in the US are linked to an HIV care provider,
5,8
 with 
greater evidence of linkage within the past decade.
5
 Approximately three-quarters of persons 
linked to care, enter care within 4 months of diagnosis.
5
 Data suggests that persons diagnosed at 
emergency and urgent care departments that are located on the same premises as HIV medical 
care have a higher likelihood of being linked to care than persons diagnosed at testing-only sites 
such as health departments or community-based organizations.
5
 Additional factors associated 
with earlier linkage to care include male sex, older age, white race, no history of intravenous 
drug use, having insurance, positive social interaction, being diagnosed with AIDS, use of case 
management services, mental health services, substance abuse treatment at the time of diagnosis, 
being diagnosed at the time of first HIV test, having a regular source of medical care before the 
9 
 
diagnosis, the presence of symptoms, and access to transportation.
13,31,53-61
 Short-term case 
management interventions at testing sites that help patients navigate the HIV care landscape 
improve both the number of people linked to HIV care and shorten the time between diagnosis 
and entry into care.
54,62
 
  Most HIV-infected persons do not present for HIV testing near the time of infection.
63
 
Persons presenting at an advanced stage of immunosuppression are at high risk of adverse 
clinical events and death.  These persons are also more likely to respond poorly to treatment.
64
 
The median CD4 count at first presentation for HIV care has increased annually over the past 
decade,
65,66
 suggesting improvements in testing and linking patients to care at an earlier stage of 
disease. However, a high proportion of patients first present to care at CD4 counts less than 350 
cells/mm
3
, the level at which ART initiation was recommended in the US between 2008 and 
2010.
67
 Because a recommended CD4 threshold for ART initiation no longer exists,
68
 earlier 
entry into care and initiation of treatment has to the potential to be even more beneficial to the 
long-term health and survival of both the HIV-infected person and their partners. 
Retention in Care: Sustained high-quality HIV care maximizes treatment outcomes in patients.
36
 
A successful “test-and-treat” prevention strategy is dependent upon efficient and effective means 
of entering and retaining patients in care.
69
 The US Department of Health and Human Services 
recommends that most HIV patients have medical visits for monitoring CD4 cell count and viral 
load (VL) every 3-4 months. Patients who are adherent to ART regimens with sustained viral 
suppression and a stable clinical status may extend the time between visits and be asked to return 
every 6 months.
67
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It is estimated that between 40%-50% of patients aware of their HIV status are not 
engaged in regular care.
5,8,70
 Missed visits within the first year of HIV care have been associated 
with decreased likelihood of receiving ART, higher rates of ART failure, increased HIV 
transmission risk behavior, increased hospitalization rates, and reduced long-term survival.
3,71-75
 
Younger age, black race, female sex, less advanced HIV disease, few or no HIV co-morbidities, 
greater distance to care, lack of health insurance, lower socioeconomic status (SES), rural 
residence, and shorter time for entry into HIV care have been associated with poorer engagement 
and retention in care.
70,76
 Additionally, psychological factors including, acceptance of HIV 
diagnosis, substance use, mental health issues, perceived stigma, lack of an external support 
system, capability of overcoming systematic barriers such as housing or transportation, and 
previous poor experiences with health care providers have been listed as obstacles to engaging in 
and being retained in HIV care.
76,77
  
Antiretroviral Therapy: Successful HIV treatment suppresses HIV to undetectable levels, 
increasing long-term survival, reducing disease-related morbidity, and decreasing ongoing 
transmission.
1,2,78
 HIV-infected persons actively engaged in care have four main barriers to 
successful treatment with ART: 1) delay or failure to initiate ARTs, 2) discontinuation of therapy 
due to adverse effects or other competing priorities, 3) poor adherence to therapy, and 4) viral 
resistance to ARTs. Under current recommendations in the US, all HIV-infected persons in care 
are eligible for treatment; however 25% are not receiving therapy.
8,68
  
The HIV Treatment Cascade and Ongoing Transmission: The HIV treatment cascade is an 
effective tool to monitor the HIV epidemic in the US. The contribution of each stage to HIV 
transmission depends not only on its size, but also the behaviors and infectiousness of persons in 
the stage. Based on previous analyses, ongoing transmission may be more likely to be attributed 
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to persons who have yet to be diagnosed, persons diagnosed but out of care, or persons in care 
with unsuppressed vial loads.
1,10,11
 Accurate estimation of the relative contribution of each 
cascade stage to HIV transmission is critical to optimize HIV prevention strategies.  
Considerations about HIV Diagnosis and Care in the South 
Most research assessing predictors of delayed HIV diagnosis and presentation to medical 
care in the US come from studies based in large urban centers, primarily on the East and West 
coasts. These predictors may not be generalizable to the South. The tax-base of Southern state 
governments is lower than states from other parts of the US, limiting their ability to provide 
optimal disease prevention and treatment.
79
 In general, there are fewer providers experienced in 
HIV-care in the South, resulting in a health infrastructure that is less equipped to identify and 
handle the epidemic.
19,27,79
 While the South has made improvements in prevention efforts in 
recent years, with reductions in both the number and rate of new HIV diagnoses,
19
 much work 
remains to increase both testing and care services for HIV-infected persons.   
Surveys of local HIV testing sites in the South indicate that the overwhelming majority of 
HIV testing is conducted at health departments, suggesting testing services are available and 
accessible in most rural counties in the region.
34
 However, sites that provide HIV care and 
treatment are less common,
34
 potentially inhibiting the receipt of quality HIV care and treatment 
in the South.
34
 Case managers identify major barriers to care in the South as the perception of 
stigma against people living with HIV/AIDs, lack of housing for person with HIV/AIDS, a lack 
of accessible transportation for clients, distance to care facilities, inadequate service 
infrastructure, and a distrust of privacy and confidentiality in the healthcare system in the 
South.
34,80
 Health department providers tend to report that their clients travel longer distances 
from the health department to the nearest treatment facility, while providers at treatment facilities 
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have indicated travel time to be much shorter.
34
 Providers at these treatment facilities may base 
their opinions about access to care and distance traveled on their current clients, many of whom 
are referred to care because they live nearby the treatment facility. These facilities may be less 
likely to see patients who live in remote parts of the region and experience difficulties related to 
accessing, linking to, and engaging in care.
34
 
Poverty and lack of health insurance make it difficult for many Southerners secure 
adequate health care.
79
 The South includes 9 of the 10 states with the highest proportion of 
people living in poverty in the US.
21
 The high levels of poverty in the South limit both the ability 
of the person to access care and also the ability of the states to allocate the resources necessary to 
provide adequate testing and care services to HIV-infected persons.   
Many HIV-infected persons rely on Medicaid, Medicare, disability insurance, the Ryan 
White Comprehensive AIDS Resource Emergency Act, and the AIDS Drug Assistance Program 
(ADAP) to receive necessary care and treatment in the South.
31,70
 However, Medicaid and 
disability eligibility is more restrictive in Southern states, and even if a person qualifies, benefits 
tend to be lower in Southern states.
81,82
 Approximately one-quarter of all HIV-infected persons in 
NC receive funding from Ryan White Part B and/or ADAP.
16
 Many Southern states contribute 
less than the national average of 16% of the state’s ADAP funding83 During the recent recession, 
many states cut ADAP benefits and capped enrollment, leaving some HIV-infected persons 
waiting for ART. In 2011, 90% of HIV-infected persons on ADAP waiting lists lived in 
Southern states.
84
 These delays can be expected to increase morbidity, mortality, and HIV 
transmission. 
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Prevention and treatment of HIV/AIDS are further complicated in the South by the high 
prevalence of HIV-infected persons living in rural areas.
79
 The wide geographic dispersion of 
rural residents adds to the complexity of planning and delivering HIV testing and treatment 
services. Rural residents are less likely to be tested for HIV and are more likely to be diagnosed 
at a later stage of disease than urban residents.
12,85
 At entry into care, rural residents are more 
likely to have more advanced disease and decreased 2 year survival than urban residents.
13
 
However, overall survival has improved for both urban and rural residents alike over the past 
decade.
13,66
 Data suggest that most rural residents living with HIV seek medical care in nearby 
urban settings, primarily because of a perceived lack of adequate medical infrastructure and a 
perceived lack of confidentiality among community members, including family, friends, 
providers, and pharmacists.
79,86
 Additionally, greater stigma related to HIV infection has been 
identified in rural areas further complicating efforts to provide HIV/STI prevention and 
treatment.
27,86
 
The failure to utilize testing and care services is not a unique phenomenon to the 
American South.  However, the reasons for delayed testing and non-engagement in care are 
distinct.  The dispersed geography of the region has resulted in greater distances between testing 
sites and care providers. High levels of poverty in the South have made it difficult for both the 
person to access and the states to provide appropriate HIV care.  Deep-rooted cultural norms 
influence the perception of disease risk and stigma, reducing the likelihood of early testing. In 
order for potential test-and-treat prevention strategies to succeed in the South, structural 
improvements in testing and linkage to care may be warranted.   
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Testing and HIV Staging 
Diagnosing persons with HIV within months of acquisition is of increasing interest to 
researchers. The events in the first few months of infection predict the course of the disease in 
the individual,
87-89
 making methods to identify early stage infection important. Persons with early 
stage infection have a higher risk of transmitting the disease than persons with chronic 
infection
90
 due to elevated virus in the blood.
91
 Detecting early infection can help public health 
officials and healthcare providers intervene and reduce the potential for future onward 
transmission. Early stage disease can be divided into Acute HIV (AHI) and Recent HIV (RHI). 
Detection of Acute HIV Infection:  Acute HIV (AHI) is defined as the 3 to 4 week period from 
HIV acquisition until seroconversion
92
 where HIV RNA is present before the patient has 
developed anti-HIV antibodies.  The p24 antigen (Ag) is also usually detectable within a few 
days of the onset of viremia. As the host’s immune system initiates a response, levels of both the 
virus and the p24 Ag fall.
93
 HIV RNA remains detectable after the early stages of HIV infection, 
but usually at levels that are much lower than during the acute phase.  Conversely, the p24 Ag 
usually becomes undetectable until the degradation of the host immune system associated with 
late-stage disease, typically around 10 years post-infection.
94
 The initial immune response begins 
with a virus-specific Immunoglobulin (Ig) M response that is highly variable in both intensity 
and duration.
94
 The IgM response generally peaks within 1-2 weeks after infection and falls to 
background levels 1-2 weeks later. At the same time, a high-titer IgG response develops.
94
 
[Figure 2.2]  
Transmission risk is high during AHI due to elevated virus in the blood and genital 
secretions.
95-97
 AHI is often characterized by a set of flu-like symptoms that are often too vague 
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or nonspecific to lead to a diagnosis.
98
 AHI also may go unrecognized because antibodies are not 
present for traditional serological tests to detect.
99,100
  
HIV RNA can be detected in the blood within a few days of infection.
91
 Nucleic acid 
amplification technology (NAAT) testing is the most sensitive test for diagnosing AHI.
94
 Pooled 
NAAT screening is a cost-effective method for detecting HIV RNA during the acute stages of 
disease. In 2002, the NC Division of Public Health (DPH) was one of the first health departments 
in the US to implement NAAT pooling through the Screening and Tracing Active Transmission 
(STAT) program, a state-wide strategy of screening for AHI at all public HIV testing sites.
101
 
Between 2002 and 2013, all antibody-negative specimens were tested for HIV RNA using 
pooled NAAT screening per STAT program protocol. Positive NAAT pools were further divided 
until HIV RNA is detected in a single sample and the person with AHI can be identified. Using 
this methodology, 1.2 per every 10,000 HIV tests in NC were identified as having AHI and 3.3% 
of all positive diagnoses in the state were diagnosed with AHI.
102
 This methodology for detecting 
AHI has been implemented in other areas, both domestic and international.
100,101,103-107
  
Alternative strategies to identify HIV include 3rd generation antibody tests, p24 enzyme 
immunoassay (EIA) antibody tests, and other developmental nucleic acid tests.  Third generation 
EIA tests can detect IgM anti-HIV-1 antibodies.
98
  In the past, tests for p24 antigen have been 
highly specific, but only exhibited moderate sensitivity (70-80%) for preseroconversion HIV.  
Newer 4th generation EIA tests can simultaneously detect viral p24 antigen and antiviral 
antibodies.
98
 These tests may detect HIV within three days of the first detection by NAAT 
testing.
98
 In November 2013, 4
th
 generation testing was implemented in NC. A diagnosis of AHI 
was re-defined as a positive 4
th
 generation EIA and negative multi-spot rapid test in the presence 
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of HIV RNA. It is anticipated that a rapid point-of-care test will be developed in the future to 
diagnose AHI.
91,98
 
Detection of Recent HIV Infection in NC: Persons with RHI have already experienced 
seroconversion, but are still early in their infection.  The exact time period cut-off for recent 
infection varies from study to study and can be anywhere from 3 to 9 months after infection.
108-
111
 A general consensus emerged among researchers that the ideal time period defining RHI was 
around 6 months.
94
 In general, during RHI, the concentration of HIV in blood remains somewhat 
elevated as compared to chronic infection, though not as high as during AHI.
91
  
The BED IgG-Capture Enzyme Immunoassay (BED assay) is the most frequently applied 
test to identify recent HIV infection.
112
 The BED assay measures the ratio of specific anti-HIV 
IgG for HIV-1 subtype B, E, and D to total IgG in a sample. The smaller the ratio, the more 
likely the person was recently infected. The result is reported as a standard optical density 
(SOD), a continuous measure that describes the relative concentration of anti-HIV IgG. The 
period of time during which the SOD is below a threshold predetermined to define “long-
standing” infection is termed the recency period.18,94,109 The BED assay lacks specificity, with a 
proportion of persons with long-standing infection, severe immunosuppression, or on 
antiretroviral therapy being misclassified as a RHI.
112,113
 AIDS is characterized by a failed 
immune system, which is associated with a decline in anti-HIV antibody levels, impacting the 
specificity of the BED assay.
112
  It has been estimated that the misclassification rate due to AIDS 
diagnoses is 2-3%.
114
 It is not fully understood why infected persons on ART are misclassified as 
recent, but it is thought to be related to the suppression of viral replication by ART which results 
in the removal of the chronic stimulus to the humoral immune response and leads to a decline in 
anti-HIV antibody titer.
94
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To correct for potential misclassification individual level information pertaining to ART 
use, previous HIV testing and AIDS diagnoses are used to identify non-recent samples and 
exclude samples from BED assay testing. If RHI identified by BED testing will be used for 
estimating incidence at the population level, correction estimators can be used to account for the 
imperfect specificity of the BED assay.
17,18,112
 A recently published approach, the multiassay 
algorithm, uses several data sources (BED-assay, an antibody avidity assay, HIV VL, and CD4 
cell count) to estimate a more sensitive measure of incidence in the population.
110,115,116
 
The Serologic Testing Algorithm for Recent HIV Seroconversion (STARHS) combines 
diagnostic testing (confirmed HIV antibody-positive) and testing for recent infection using the 
BED assay to identify RHI to create incidence estimates in the population. Since 2004, the CDC 
has identified 25 jurisdictions, including NC, to conduct HIV incidence surveillance. The NC 
HIV Incidence Surveillance project team works in collaboration with the CDC to estimate RHI 
in NC using STARHS methodology.  Currently 50-60% of all newly positive HIV blood samples 
from NC are forwarded to CDC labs for STARHS testing.
117
   
Detection of Chronic HIV and AIDS: Chronic HIV (CHI) can be defined as the time period 
between RHI and AIDS.  Most persons with a confirmed HIV antibody-positive test as their first 
HIV test are considered to have CHI.  Only those tests identified through the BED assay and 
STARHS to have a SOD below the recency period threshold would be reclassified from CHI to 
RHI.  AIDS is classified as late stage HIV and is characterized by a damaged immune system 
that has difficulty fighting diseases and certain cancers. A diagnosis of AIDS occurs with a 
laboratory confirmation of HIV infection and at least one of the following: 1) CD4 cell count of 
less than 200 cells/mm3, 2) CD4 count that is less than 14 percent of all lymphocytes, or 3) a 
diagnosis of one or more AIDS-defining illness.
118
 [Table 2.1]  
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Surveillance Data and the HIV Treatment Cascade 
HIV surveillance systems collect demographic data, as well as testing, clinical, 
laboratory, and vital status information on all HIV case reports.  Originally, information was 
only collected at the time of diagnosis.  As of 2009, 38 of 50 states and the District of Columbia 
required reporting of either all CD4 cell counts or all HIV VL.  The remaining states either did 
not require any reporting of CD4 cell counts and HIV VLs, or required reporting within a 
specified range of values.
118,119
 Prior to July 2013, NC required CD4 cell counts <200 cells/mm
3
 
or <14% and all detectable VLs (>20 copies/mL) be reported to the NC DPH.
117
  
When using surveillance systems for research purposes, it is preferred that high-quality 
surveillance data with complete capture of HIV-related laboratory results be used.
120
 However, 
data can be missing in many surveillance systems. Reports of new HIV diagnoses and their 
clinical lab values may be delayed or incomplete, thus affecting the real-time tracking of testing 
and care patterns in a population. As more health departments move towards electronic reporting 
of testing and clinical lab values, this should become less of a limitation. Incomplete reporting of 
deaths and migration out of a jurisdiction distorts estimates of the total number of HIV-infected 
persons in a place and makes the estimation of their care and treatment status difficult.
121
  
CD4 and HIV VL tests have been used as a proxy for the receipt of medical care in a 
number of epidemiologic studies.
5,53,59,60,119,120,122-126
 Studies have suggested that state databases 
such as eHARS (electronic HIV/AIDS Reporting System) generate the lowest estimates of entry 
and retention in care as compared to studies utilizing patient self-report or clinic medical record 
searches.
5,121
 Further, it has been demonstrated that using a single VL or CD4 measurement as a 
proxy for receipt of HIV care may overestimate the number of people currently in care.
122
 
Linkage across HIV surveillance databases and with for-profit data warehouses containing 
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current residential information could improve the accuracy in estimating the care status of HIV-
infected persons in a specific jurisdiction.
121
  
Despite its limitations, surveillance records reflect real-world, care-seeking and treatment 
behaviors that are unmodified by study monitoring. The limitations of HIV surveillance systems 
should be considered and noted when analyzing data originating from these sources. Active 
surveillance can increase the number of CD4 and HIV VL tests reported and consequently, 
increase the number of HIV-infected persons identified as receiving HIV care.
124
  
Summary 
Ensuring timely access to HIV testing, care, and treatment is challenging. Understanding 
the context and settings in which transmission risk is increased may lead to more robust and 
effective prevention interventions. It is anticipated that the findings from this dissertation, will 
improve the identification of at-risk populations in NC and the allocation of resources towards 
the areas and populations most likely to be affected by HIV. Improvements in preventative 
services to overcome discrepancies in undiagnosed HIV infection and inadequate engagement in 
HIV care among persons involved in active transmission networks could have a tremendous 
impact on HIV incidence in this and similar settings.  
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Tables and Figures 
Figure 2.1 The HIV treatment cascade in the United States  
 
Courtesy of Mugavero, 2011
39
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Figure 2.2 Evolution of key viral and serological markers during the first weeks after HIV-1 
infection 
 
Courtesy of Murphy, 2008.
94
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Table 2.1 AIDS-defining Illnesses 
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CHAPTER THREE: DESCRIPTION OF DATA SOURCES 
The Counselling and Testing Report Database: 
 Persons requesting an HIV test from a publicly-funded testing site in NC, including local 
health departments, complete a counselling and testing report (CTR) form at the time of testing 
[Appendix 1]. Demographics, testing history, zip code, transmission risk factors, and site of 
testing are captured on the CTR forms are linked to HIV test results processed by the NC state 
laboratory of public health by a de-identified barcode number. Data for both HIV-infected and 
HIV-negative tests is entered in the CTR database maintained by the NC Division of Public 
Health (DPH).  All HIV-positive cases in the CTR system are linked to electronic HIV/AIDS 
Reporting System (eHARS) through an eHARS identification number.   
The Electronic HIV/AIDS Reporting System: 
 The DPH monitors all persons either diagnosed with HIV in NC or diagnosed with HIV 
in another state and now living in NC in eHARS. Data collected and entered in eHARS includes 
basic demographic and risk factor information, date of HIV and AIDS diagnosis, residence at 
HIV and AIDS diagnosis, and HIV or AIDS diagnosis site and address. Selected laboratory 
values, including CD4 cell counts <200 cells/mm
3
, and detectable viral loads, are included in 
eHARS. 
Results from Serologic Testing Algorithm for Recent HIV Seroconversion (STARHS) 
testing is also stored in eHARS. STARHS is a 2 test algorithm in which the first test is used to 
determine whether a person is HIV-positive on standard EIA tests. The EIA test is followed by
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the BED capture enzyme immunoassay which measures the ratio of specific anti-HIV 
immunoglobulin G (IgG) for HIV-1 subtype B, E, and D to total IgG in a sample. The lower the 
ratio, the more likely a person was infected within the past 6 months can be classified as recently 
infected. The result is reported as a standard optical density (SOD), a continuous measure that 
describes the relative concentration of anti-HIV IgG. The period of time during which the SOD 
is below a threshold predetermined to define “long-standing” infection (approximately 156 days 
from infection), is termed the recency period. Since 2005, the NC DPH has collected and sent 
remnant samples of confirmed HIV antibody-positive serum from the NC state laboratory to the 
CDC STARHS designated laboratory for BED-assay testing. STARHS results are returned to the 
NC DPH and entered into eHARS. 
The Screening and Tracing Active Transmission Database: 
The Screening and Tracing Active Transmission (STAT) program is a collaboration 
between the University of North Carolina (UNC) and NC DPH to identify persons diagnosed 
with acute HIV (AHI) at the state laboratory via nucleic acid amplification test (NAAT) pooling 
procedures for all negative or indeterminate HIV antibody tests.
100,127
 Positive NAAT pools are 
subdivided until HIV RNA is detected in a single sample and a person with AHI can be 
identified. This process typically takes between 10-14 days before results are released and the 
person is notified of their disease status.
117
 AHI cases screened and identified via “community” 
testing facilities (e.g. emergency departments, urgent care centers, student health centers, or 
primary care clinics) are also tracked by the STAT program. In the community settings, AHI was 
defined by a negative or indeterminate antibody test and reproducibly detectable HIV RNA or a 
positive antibody test with seronegative documentation within the preceding 30 days of the 
positive test date.   
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Disease Intervention Specialists (DIS) contact all persons newly-diagnosed with AHI 
(index AHI) within 72 hours of release of HIV test results and perform an initial interview, 
conduct confirmatory HIV testing, and make referrals to HIV care providers, as necessary. In 
addition to standard information about the testing sites, reasons for HIV testing, demographics, 
HIV testing history and risk factors, DIS also collect detailed information about acute retroviral 
symptoms, risk behavior, and sexual and needle-sharing partnerships within 8 weeks of the 
original HIV diagnosis date for all acute cases. DIS attempt to find, counsel, and provide HIV 
testing for all named sexual and needle-sharing partnerships within 8 weeks of the index AHI 
diagnosis date for the STAT program. DIS search the Sexually Transmitted Disease 
Management Information System (2002 to November 2012) or the NC Electronic Disease 
Surveillance System (NC EDSS) (November 2012-present) to identify partners who have been 
previously-diagnosed and verify HIV diagnosis dates and most recent clinical lab values (VL and 
CD4). For previously-diagnosed partners reporting current HIV care, DIS follow-up with 
providers to classify the care and treatment status of partners in the 6 months prior to 
transmission. Prior to 2013, index AHI cases were also required to sign a HIPAA form for DIS 
to report detailed testing and sexual behavior with named partners as part of the STAT program. 
De-identified data collected about all index AHI cases and their partners are reported on a 
biweekly conference call with state officials and researchers at UNC. DIS complete three STAT 
forms for each AHI: the STAT log form to summarize testing and referral to care, the STAT 
Symptoms and STI form, and the STAT Partner log [Appendix 2].  Completed forms are faxed 
to the STAT data manager at UNC for entry into the STAT database.  
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CHAVI-001: 
Between 2006 and 2011, all suspected and confirmed AHI cases via the STAT program 
were referred for evaluation at UNC or Duke University, and offered enrollment in the Center for 
HIV/AIDS Vaccine Immunology 001 Study: Acute HIV Infection Prospective Cohort Study 
(CHAVI-001), a longitudinal study examining the HIV-1 virus, host response, genetic factors 
that determine HIV transmission, and viral set point.
128
   
In addition to the basic demographic and testing information collected by the DIS, 
laboratory data, including VL and CD4 cell count were collected for all CHAVI-001 patients at 
the time of enrollment. All sexual or needle-sharing partners within 12 weeks of the index AHI 
diagnosis date who were located by either a DIS or the CHAVI-001 field coordinator were also 
offered enrollment in CHAVI-001, regardless of HIV status. HIV-uninfected partners received 
HIV testing and counseling at each study visit during follow-up, while VL and CD4 were 
collected at enrollment and each study visit for HIV-infected partners on CHAVI-001. Data 
collected via CHAVI-001 was maintained in a separate database through Duke University by the 
Statistical Center for HIV/AIDS Research and Prevention. 
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CHAPTER FOUR: RESEARCH DESIGN AND METHODS 
Aim 1: HIV transmission in NC 
Study Design 
For this aim, we estimated 1) the cascade landscape of all named partners and 2) the 
relative contribution of persons unaware versus aware of their HIV infection to ongoing 
transmission in NC. If aware, the care, treatment and viral suppression status of potential 
transmitting partners were also considered. This cross-sectional assessment relied on named 
sexual and needle-sharing partner information of acutely-diagnosed cases (index AHI case) 
collected as part of the STAT program. A complementary cross-sectional analysis of 
phylogenetically-linked partnerships identified via CHAVI-001 was also conducted. 
Study Population 
Persons 16 years of age or older, diagnosed with AHI in NC between November 2002 
and June 2013 and identified via the STAT program were included in the main analysis. 
Additionally, all sexual and needle-sharing partners named by the index AHI case in the 8 weeks 
prior to their diagnosis were included. 
For the complementary analysis among CHAVI-001 data, all index AHI cases identified 
via the STAT program who enrolled on study between May 2006 and December 2011 and their 
named sexual and needle-sharing partners within the past 12 weeks were included for analysis.
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Data for named partners could not be linked between the STAT program and CHAVI-001, 
therefore the number of partners and their characteristics may be different between data sources.  
Exposure Assessment 
All named partners were initially classified as identifiable or anonymous. Anonymous 
partners were not pursued by DIS because identifying information provided by the index AHI 
case was absent or incomplete. For identifiable partners, the index AHI case provided enough 
information for DIS to identify the partner and classify as previously-diagnosed or undiagnosed. 
Undiagnosed partners who were unlocatable or unwilling to be tested were classified as 
“Unknown.” The remaining partners were tested for HIV and were subsequently classified as 
“HIV-uninfected,” “New AHI,” or “New chronic HIV infection (CHI).” Among partners not 
diagnosed with AHI or AIDS at the time of the index AHI case diagnosis, Serologic Testing 
Algorithm for Recent HIV Seroconversion (STARHS) testing results were used to approximate 
recent (≤6 months) from longstanding infection (>6 months) at the time of transmission using a 
normalized optical density cut-point of <0.8 on the BED assay. Care and treatment status of 
previously-diagnosed partners was confirmed by DIS, to classify partners as “in care” (visit with 
an HIV provider during the 6 months prior to AHI diagnosis) or “on ART” (receipt of ART or 
VL below the detectable limits of the reported test during the 6 months prior to the index AHI 
case diagnosis).  
Diagnosis status (new AHI, new CHI, or previously-diagnosed) was assigned to all HIV-
infected partners. For previously-diagnosed partners for whom complete HIV care and treatment 
data were reported by DIS, we assigned care and treatment status at the time of the index AHI 
case diagnosis (not in care, in care and not on ART, in care and on ART). Because quantitative 
VLs are not collected as part of the STAT program, we extracted all partner VLs reported in 
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eHARS between 6 months before to 2 months after the index AHI case diagnosis date. To assess 
viral suppression (<200 copies/ml) status near transmission, we considered only the closest VL 
to the index AHI case’s diagnosis date. If VLs for previously-diagnosed partners were identified 
both before and after the index AHI case diagnosis date, the earlier VL was used to assess viral 
suppression near transmission. 
Between May 2006 and December 2011, all index AHI cases identified via the STAT 
program were referred for evaluation at the University of North Carolina at Chapel Hill (UNC-
CH) or Duke University, and offered enrollment in CHAVI-001. Blood samples were collected 
from patients at the time of enrollment in addition to basic demographics and HIV testing 
history. The HIV status for all partners within 12 weeks of the diagnosis date of each index AHI 
case was collected by the CHAVI-001 field coordinator in a method similar to that described 
with the STAT program. Locatable partners were offered enrollment in CHAVI-001, regardless 
of HIV status and blood samples were collected for HIV-infected partners at enrollment.  
Cell-free blood plasma was extracted from blood samples provided by index AHI cases 
and HIV-infected partners enrolled in CHAVI-001 to isolate viral RNA using the QIAMP Viral 
RNA Mini Kit (Qiagen). For each sample, approximately 10,000 to 20,000 viral RNA copies 
were extracted and eluted. Single genome amplification of the env gene was performed using a 
limiting dilution, as previously described.
129-138
 Additionally, bulk sequences of pro-pol 
amplicons were derived from Genosure® or the TRUGENE® HIV-1 assay (Siemens Healthcare 
Diagnostics, Tarrytown, NY).  
DNA sequence alignments on either full length env or pro-pol amplicons were performed 
using Clustal W 2.0.7.
136
 Phylogenetic trees were generated using a neighbor-joining method 
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(MEGA 4.0) with inclusion of random subtype B sequences.
137
 Transmission pairs were 
confirmed by co-clustering on phylogenetic trees with high bootstrap values (>95%).  Pairwise 
DNA distances computed using MEGA 4.0 and Highlighter plots (www.hiv.lanl.gov) were 
visualized to confirm transmission pairs had identical or nearly identical sequences. 
Once a phylogenetically-linked transmission pair was identified, Bayesian analysis was 
used to distinguish the donor from the recipient in the pair based on the date of the blood sample 
and contact dates reported during the field investigation. Markov Chain Monte Carlo simulation 
was used to estimate the time of divergence from the most recent common ancestor in Bayesian 
Evolutionary Analysis by Sampling Trees (version 1.4.8), as previously described.
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Statistical Analysis 
Each index AHI case was classified according to the pattern of information collected 
about the HIV status of named partners [Table 4.1]: A) the HIV status of all partners is known 
and only one is HIV-infected, B) >1 HIV-infected partner (with or without additional 
unknown/anonymous partners) or one HIV-infected partner with additional unknown/anonymous 
partners, C) only partners of unknown/anonymous status and D) no HIV-infected or partners of 
unknown/anonymous partners status.  
Diagnosis status and when available, care and treatment status, were estimated for the 
most likely HIV-infected transmitting partner named by index AHI cases.  For index cases 
naming only 1 HIV-infected partner with the status of all other partners known (Type A), this 
partner was assumed to be the most-likely transmitting partner. The proportion of HIV-infected 
partners and 95% confidence intervals (CI) by HIV diagnosis, care and treatment status were 
estimated.  
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For index AHI cases naming >1 potential transmitting partner (HIV-infected and/or 
anonymous/unknown status) as part of the STAT program investigation, we were less certain of 
the most likely-transmitting partner. To provide a reasonable estimate of the diagnosis, care, and 
treatment characteristics of the most likely transmission source among named HIV-infected 
partners for these index AHI cases (Type B), we repeatedly, randomly sampled HIV-infected 
partners 1000 times with replacement. The repeated sampling allows for an accurate estimate of 
diagnosis, care, and treatment status to be made among multiple HIV-infected partners are 
named.
140
 The proportion and 5th and 95th percentiles of sampled HIV-infected partners by HIV 
diagnosis, care, and treatment status were then reported. For index AHI cases naming 1 HIV-
infected partner (Type B1), the probability of selection was 1, while the probability of selection 
for index AHI cases naming >1 HIV-infected partners (Types B2 and B3) was 1/(number of 
named HIV-infected partners). Index AHI cases naming only potential transmitting partners of 
unknown status (Type C) were not included in the repeated sampling analysis as HIV diagnosis, 
care and treatment status were unspecified and the most likely transmission source could not be 
estimated. 
Among phylogenetically-linked cases identified via CHAVI-001, the proportion and 95% 
Confidence Intervals (CI) of new AHI, new CHI, and previously-diagnosed partners was 
estimated. Treatment status was estimated based on the partner’s reported ART history at 
enrollment. HIV care status could not be estimated for partners identified via CHAVI-001 
because this information was not collected as part of the study and data collected via the STAT 
program could not be linked to these partners. 
All statistical analyses were conducted in SAS version 9.3 (SAS Institute, Cary, NC).  
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Aim 2: Spatial assessment of early and late stage HIV diagnoses in NC  
Study Design 
In Aim 2, we assessed the spatiotemporal clustering of new diagnoses in NC by stage of 
disease as determined by HIV testing results. Using a case-only design within the context of an 
ecological framework, we aimed to determine if and how high rate clustering by disease stage at 
diagnosis has changed in NC over time. We used surveillance data maintained by 3 different NC 
Division of Public Health (DPH) sources: 1) the NC Counselling and Testing Report (CTR) 
database, 2) the NC STAT program, and 3) the NC electronic HIV/AIDS Reporting System 
(eHARS). The use of data collected for surveillance purposes represents real-world HIV testing 
behaviors that have not been modified by study monitoring. 
Study Population 
All persons aged 16 years and older and newly-diagnosed with HIV in a publicly-funded 
testing site [Table 4.2] between July 2005 and June 2013 and residing within a 52-county study 
area in central NC [Figure 4.1] were considered for analysis. We geocoded all cases to their self-
reported address at the time of diagnosis as recorded in eHARS using an ESRI (Redlands, CA)-
supplied NC street basemap and the testing population to their self-reported zip code at the time 
of diagnosis as recorded in the CTR database to a population-weighted random location in a 
ESRI NC zip code basemap using ArcGIS (version 10.1, ESRI). Persons whose testing was 
conducted at a correctional facility were excluded from analysis as their motivation for testing 
may be different.  
 To estimate the underlying testing population at a publicly-funded testing site, we 
deduplicated HIV tests reported in the CTR system based on recorded name, date of birth, race, 
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and gender using The Link King Program (version 7.1.21, Camelot Consulting Olympia, 
Washington). Spelling and data entry errors were not uncommon in this dataset, so we relied on 
both deterministic and probabilistic linkages generated by The Link King Program.  
Probabilistic linkage occurs through statistical analysis of the similarity between data 
elements record-pairs. Weights and scaling factors based on the available data are used to 
generate a score for each record pair. Weights reflect the relative importance of specific data 
elements in predicting a match and scaling factors adjust the weights based on the frequency 
with which that specific data value occurs in the data being analyzed.  Cut-points for the score 
are derived to identify definite matches, possible matches and non-matches.
141
  
In deterministic linkage, criteria used to indicate a match between records are set outside 
of and known prior to the linking process. The Link King Program allows for some discrepancy 
in the deterministic linking process through the incorporation of “less certain” equivalence 
algorithms.
141
   
The sensitivity and positive predictive value of linkages produced by The Link King 
Program have been found to be >90%, when using reviewers’ decision as the gold standard.141 
We used the default settings to indicate a match between records in all instances except for the 
following: 1) no minimum disagreement weight was set for zip codes (i.e. zip codes could be 
different and the records could still match) and 2) we did not pre-specify the minimum weight 
for probabilistic linkages. 
Using The Link King, we generated 2 estimates of the testing population in which we 
deleted non-exact matches (conservative estimate) or kept non-exact matches (liberal estimate) 
categorized in the lowest linkage certainty categories (4, 6, and 7) by the Link King program 
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(version 6.4). The testing population based on the conservative estimate was used to calculate 
testing rates for the main analysis.  
Exposure Assessment (Stage of Disease at Diagnosis) 
Using a 3-step process, we assigned all new diagnoses a stage of disease at diagnosis 
(AHI, RHI, Chronic HIV Infection (CHI), and AIDS) based on STAT, STARHS, and standard 
HIV testing results [Figure 4.2]. First, STAT cases were linked to eHARS to identify all cases 
diagnosed with AHI. Next, all cases diagnosed with AIDS in eHARS (as defined by either a CD4 
cell count <200 cells/mm
3
, a CD4 count < 14% of all lymphocytes, or a diagnosis of one or more 
AIDS-defining illnesses) at the time of or within 6 months of an HIV diagnosis were identified. 
For the remaining cases, STARHS results were used (when available) to approximate recent (≤6 
months) from longstanding infection (>6 months), based on a normalized optical density cut-
point of <0.8 on the BED assay.
17
 All other diagnoses were classified as CHI. If non-AHI, non-
AIDS cases did not have STARHS testing, their disease stage could not be determined. These 
cases were therefore excluded from analysis. Since diagnosis during AHI is rare in NC,
102
 AHI 
and RHI were considered together as one stage of disease, Early HIV infection (EHI) for Aim 2.  
Outcome Assessment (HIV diagnosis rate by stage of disease and testing period):  
All geocoded cases were aggregated to the 2010 census tract boundaries to maintain 
confidentiality while still exhibiting variability in space.
142
 The study area contains 1597 (73.1%) 
of the census tracts in NC in 2010. Some census tract boundaries changed when the results of the 
2010 census were released. A difference in clustering due to these changes was expected to be 
minor.
143
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 Each case was assigned a testing period of diagnosis based on when they were diagnosed 
in relation to the release of the CDC recommendations for opt-out testing in September 2006. 
Assuming a slight delay between the release of the recommendations and the implementation of 
opt-out testing in practice, we classified cases diagnosed between July 2005 and December 2007 
as being diagnosed before CDC recommendations (Period 1). Cases diagnosed between January 
2008 and December 2010 were classified as being diagnosed immediately after the CDC 
recommendations (Period 2). Finally, cases diagnosed between January 2011 and June 2013 
were classified as being diagnosed after the recommendations with some delay (Period 3).  
 To compare disease maps across multiple time periods, we assigned HIV diagnosis rates 
[number of cases tested per tract/(number of people testing in each tract*time)] by stage of 
disease and testing period to the geographic center (centroid) of each census tract for subsequent 
analysis, estimation, and mapping. 
Statistical Analysis: 
BME: Bayesian Maximum Entropy (BME), specifically the uniform model extension of BME 
(UMBME), was used to describe the changes in spatial distribution of HIV diagnosis rates by 
stage of disease in each testing period. BME is a geostatistical technique in which disease rates 
can be estimated for a given interval by using the surrounding observations in both space and 
time.
144-146
 The main output of this method is a series of spatially-dependent maps. For relatively 
rare diseases, such as HIV, calculating crude rates from routinely collected surveillance data 
indexed at a small geographical resolution poses statistical problems due to the sparse nature of 
the data.
147-150
 Error due to sampling variability introduces observational noise into the map that 
may obscure and therefore lead to incorrect inferences about HIV diagnosis patterns in NC. 
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BME is a useful tool in the evaluation of rates because it is able to separate this noise from actual 
disease patterns to provide an accurate picture of disease clusters.
151
 
In BME methodology, a spatiotemporal random field X(s,t) is used to assign probabilities 
to a set of possible distributions that describe the disease in space, s, and time, t. These 
probabilities provide the basis for the prior (“total”) knowledge that is known about the disease.  
Total knowledge is divided into the general knowledge base, G, and the site-specific 
knowledge base, S. The general knowledge base includes theories, laws, covariance structures, 
and mean trends. This information is processed using the maximum entropy principle and yields 
a prior probability density function model for the spatiotemporal disease map. The site-specific 
knowledge refers to measured data over the spatiotemporal random field, X(s,t). Data measured 
with low error and high certainty are referred to as “hard data,” and data measured with high 
error and low certainty are referred to as “soft data”. This stage is a generalized form of the 
likelihood stage in traditional Bayesian methods.
146
  
A posterior pdf of the disease outcome at each estimation point is generated using a 
Bayesian conditionalization rule to update the prior pdf with the site-specific data. This results in 
a series of smoothed maps that are temporally dependent if the composite spatiotemporal BME 
approach was applied. Error maps associated with the disease estimates are also generated at this 
stage [Figure 4.3]. 
In UMBME, measurement error is assumed to be distributed uniformly around the 
observed rate in an interval the size of 1/testing population. Therefore, observed diagnosis rates 
are treated as probabilistic (“soft”) data with measures of uncertainty as defined by the uniform 
distribution interval. BMEGUI (version 3.0.1, Chapel Hill, North Carolina), the computer 
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software used to implement the BME approach, was used to conduct the composite space-time 
analyses and mapping. 
Once a smoothed map was created for each of the 3 disease stages during the 3 testing 
periods under consideration, maps were normalized to the same scale to assess percent overlap of 
high diagnosis rate areas. A cut-off point at the top 10
th
 percentile on this normalized scale was 
used to dichotomize diagnosis rates in each pixel as high versus low rates. The proportion of 
“high rate” pixels on one map that were also “high rate” on another map was assessed 1) across 
each testing period within each disease stage and 2) across each disease stage within each testing 
period. 
We varied the cut-off point used to define “high-rate” clusters in sensitivity analyses to 
the top 25
th
 and 50
th
 percentiles to evaluate the effect of the definition of “high rate” on our 
conclusions.  
Kulldorff’s Spatial Scan Statistic: The Kulldorff spatial scan statistic (SaTScan software, 
Information Management Services, Inc., Silver Spring, Maryland) was applied to identify the 
presence and location of clusters by disease stage and testing period using census tract diagnosis 
rates. High-rate clusters were identified as areas where the observed number of cases was greater 
than the expected number of cases based on spatial randomness.  
The Kulldorff’s spatial scan statistic uses a Poisson model where the observed number of 
cases is compared to the background population data and the expected number of cases in each 
census tract is proportional to the size of the population at risk (i.e. the estimated testing 
population) [74]. The null hypothesis for the Kulldorff spatial scan statistic states that the 
probability of being a case is the same in all parts of the map, while the alternative hypothesis 
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states that the probability of being a case inside the window (p) is greater than the probability of 
being a case outside the window (q).
152
 The alternative hypothesis suggests a significant degree 
of spatial clustering is present inside the window.  
A likelihood ratio test statistic was calculated for each potential cluster:  
L(z)=Lp>q/ Lp=q 
The maximum likelihood ratio (L(z)max) value is evaluated first by performing a log-likelihood 
ratio test. This test determines the approximate p-value for the L(z)max cluster using Monte 
Carlo simulation which randomly allocates cases in the study area. Potential clusters with a 
corresponding observed likelihood ratio test statistic within the upper 5% tail of the 
corresponding simulated (expected) distribution will be classified as statistically significant at 
the 0.05 level.  
The percent overlap of high-rate clusters identified via the Kulldorff spatial scan test 
statistic by disease stage-time period categories was calculated, as described in the BME 
analysis. Briefly, “high-rate” census tracts are those that the Kulldorff spatial scan statistic 
estimated to be included in a statistically-significant cluster. The percent overlap of census tracts 
identified as being involved in “high-rate” clustering by each disease stage-testing period 
category will be calculated.    
Aim 3: Distance to a testing site and stage of disease at diagnosis  
Study Design: 
 The underlying research question for Aim 3 is whether increased distance to a publicly-
funded testing site is associated with HIV diagnosis at later stages of disease. Because both the 
outcome (stage of disease at diagnosis) and the exposure (distance to testing site) will be 
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collected a single time point, this analysis will be cross-sectional in nature.  Using the home 
addresses of all newly diagnosed persons that were collected for standard surveillance purposes 
by the NC DPH and geocoded in Aim 2, we calculated the geographic (i.e. road network) 
distance between the home address and the both the 1) the HIV testing site of diagnosis and 2) 
nearest publicly-funded HIV testing site.  
In this analysis, we assumed people living near one another were more similar than those 
living farther apart from one another in terms of socioeconomic status, access to transportation, 
education, and employment and would exhibit similar HIV test-seeking behaviors. Therefore, we 
used census tract as a proxy for one’s neighborhood in log binomial models with generalized 
estimating equations to account for these second-level characteristics. These models produce a 
population averaged estimate of the risk of late stage diagnosis across the entire study areas that 
could be useful for public health officials and policymakers when deciding how and where to 
allocate resources.    
Study Population: 
 The eligibility criteria and study population for Aim 2 is identical to that used to identify 
newly-diagnosed cases for Aim 2.  
Exposure Assessment: 
Residential addresses of all new HIV cases were geocoded to an ESRI-supplied NC street 
basemap using ArcGIS, as described in Aim 2. Census tract at diagnosis was assigned based on 
the geocoded residential address.  
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 All publicly-funded HIV testing sites that provide samples to the state lab of public health 
for processing were geocoded to their physical address using the same method used to geocode 
the residential addresses of new HIV cases. The network distance (miles) between each case’s 
residential address and both 1) the testing site of diagnosis and 2) the closest publicly-funded 
testing site were calculated in ArcGIS using the Network Analyst extension.   
We assessed the most appropriate form for the continuous distance variables to model the 
association between distance and the risk for late stage diagnosis. To determine the most 
appropriate form, distance was coded continuously, as a categorical variable, and using upper 
and lower tail restricted quadratic spline variables. Risk of late stage disease and 95% confidence 
intervals were calculated and plotted for each form of the distance variables and p-values for 
trend and confidence limit ratios were assessed to determine the precision and accuracy of each 
coding method. Because the dose-response relationship increased until mile 5 and then 
plateaued, we decided to dichotomize both distance variables (≤ 5 miles versus >5 miles) to 
increase precision and parsimony.  
Outcome Assessment: 
 The main outcome under analysis is the stage of disease at diagnosis. All cases were 
assigned a stage of disease at diagnosis as described in Aim 2 (Figure 4.2). We dichotomized 
stage of disease into early (AHI and RHI) diagnoses and post-early (CHI and AIDS) diagnoses 
for all analyses for Aim 3.  
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Statistical Analysis: 
Because place frames a person’s behavior, we assessed the presence of spatial 
autocorrelation between the geocoded addresses of early and post-early diagnoses with the global 
Moran’s I statistic in ArcGIS.  
Moran’s I is defined as: 
𝐼 =
𝑁
∑ ∑ 𝑤𝑖𝑗𝑗𝑖
∑ ∑ 𝑤𝑖𝑗(𝑋𝑖 − ?̅?)(𝑋𝑗 − ?̅?)𝑗𝑖
∑ (𝑋𝑖 − ?̅?)2𝑖
 
Where N is the number of spatial units indexed by i and j. X is post-early stage disease, ?̅? is the 
mean of X, and wij is an element of a matrix of spatial weights. 
The global Moran’s I evaluates whether diagnoses are clustered, dispersed or random in 
space by stage of disease.
152
 Because the global Moran’s I, was not statistically significant 
(p=0.5), the cases were assumed to be distributed randomly in space by disease stage and it was 
not necessary to account for spatial autocorrelation in any further statistical modeling.   
Binomial risk models (log link and binomial distribution) using generalized estimating 
equations and a compound symmetry correlation matrix, were fit to estimate prevalence ratios 
(PR) and robust 95% confidence intervals (CI) for late stage diagnoses and by distance (closest 
site and site of diagnosis). Census tracts, which served as a proxy for unobserved characteristics 
(e.g. education, income, and employment), were used to account for the clustering of the 
outcome at the neighborhood level.  
Generalized estimated equations (GEE) are used to estimate the parameters of a 
generalized linear model with possible unknown correlation between outcomes.
153
 The main 
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purpose of GEE models is to estimate the average response over the population rather than 
subject (or in this case, census tract) specific responses. Our model took the following form: 
ln(P(Dij=1|Xij)) = α + β1X1 + β2X2 +β3X3 +… 
Where D is post-early stage diagnosis and X represents the set of all exposure variables for 
subject i within census tract j.  
GEE produces unbiased standard errors even if the working correlation matrix is slightly 
misspecified through the use of robust or “sandwich” variance estimation.153 Because we are 
working with hierarchical data (HIV cases within a census tract), it is unlikely that the 
correlations vary within a cluster. Furthermore, some census tracts include up to 27 cases. 
Therefore, to maintain parsimony, a compound symmetry working correlation matrix was used 
during all modeling with GEE. Compound symmetry assumes variation between census tracts is 
greater than variation within subjects and requires that only 1 parameter be estimated. 
Effect measure modification (EMM) was assessed using likelihood ratio testing. An 
interaction term was maintained in the model if the difference between the full model 
(interaction term present) and the reduced model (no interaction term) was statistically 
significant at an a priori level of p>0.15.  In this case, the null hypothesis that the interaction 
term equals 0 was rejected and variable was classified as an EMM. No variables under 
consideration (age, race/ethnicity, gender, time period, risk group, rurality, and testing site) were 
considered EMMs based on these methods. 
For all variables not considered to be EMMs, we used change-in-estimate methods to 
assess confounding of the exposure-outcome relationship in the covariates listed above. Change-
in-estimate (|ln(CoOR)|) was calculated by comparing the full model to a reduced model with the 
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potential confounder removed. This was repeated for all potential confounders. All variables that 
change the prevalence ratio estimate by less than 10% when removed should be dropped from 
the final model.  
Using these methods, no covariate was classified as a confounder. However, a review of 
the literature and construction of a directed acyclic graph [Figure 4.4] suggest the minimally 
sufficient adjustment set included race/ethnicity, rurality, and testing period. Therefore, these 
confounders were considered in all adjusted models. Because census tract was used to account 
for clustering of the outcome and was also used to determine urban/rural status, we did not 
directly adjust the models for rurality.  
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Tables and Figures 
Table 4.1 Pattern of Partner Status 
Type Number of known 
HIV-infected 
partners 
Number of known 
HIV-uninfected 
partners 
Number of 
unknown status 
partners 
A 1 ≥0 0 
B    
  B1 >1 ≥0 0 
  B2 1 ≥0 ≥1 
  B3 >1 ≥0 ≥1 
C 0 0 ≥1 
D    
  D1 0 0 0 
  D2 0 ≥1 0 
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Table 4.2 Publicly-Funded Testing Sites in North Carolina 
1. HIV Counseling and Testing Services (CTS) 
2. Sexually Transmitted Disease Clinic 
3. Drug Treatment Clinic 
4. Family Planning Clinic 
5. Prenatal/Obstetrics Clinic 
6. TB Clinic 
7. Community Health Center 
8. Prison/Jail 
9. Field Visits 
10. Outreach Testing 
11. Hospital/Private Medical Doctor 
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Figure 4.1 Study Area in Central North Carolina 
 
CAPTION: 52-county study area in central North Carolina roughly corresponds to the North Carolina 
Division of Public Health Field Services Unit Regions 2 (Charlotte), 3 (Winston-Salem/Greensboro), 4 
(Raleigh), and 5 (Fayetteville). 
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Figure 4.2 Three-Step Algorithm based on HIV testing results reported to the North Carolina 
Communicable Disease Branch used to determine stage of disease 
 
 
 
*AHI=Acute HIV infection; RHI=Recent HIV Infection; CHI=Chronic HIV Infection 
CAPTION: From the pool of all persons newly-diagnosed at a publicly-funded testing site, we 
first classified all Acute HIV infection identified by the STAT (Screening and Tracing of Active 
Transmission) program. Next, we used AIDS diagnosis dates reported in eHARS (electronic 
HIV/AIDS reporting system) to classify AIDS cases. Among the remaining cases with STARHS 
(Serologic Testing Algorithm for Recent HIV Seroconversion ) testing reported in eHARS, we 
were able to classify Recent from longstanding infection. 
  
New HIV 
Diagnosis 
Non-AHI 
Non-
AIDS 
STARHS 
Testing 
RHI 
CHI 
AIDS 
STAT 
(AHI) 
Step 1 Step 2 Step 3 
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Figure 4.3 Conceptual model of the Bayesian maximum entropy (BME) approach 
 
 
CAPTION: Conceptual model of the Bayesian Maximum Entropy Approach, courtesy of Gesink 
Law, 2006.
145
 Briefly, BME incorporates general knowledge in the form or theories, laws, mean 
trends, and covariance plots with site specific information that can be either highly accurate 
(“hard data”) or probabilistic (“soft data”) to create a posterior probability distribution function 
(pdf) of the disease outcome at each estimation point in a spatiotemporal random field, X(s,t).  
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Figure 4.4 Directed Acyclic Graph illustrating the association between Distance to a Testing Site 
and Stage of Diagnosis 
Unmeasured Confounder*  
 
Race        Age 
 
Gender      Risk Group 
 
Urban/Rural 
 
Time Period 
 
 
 
Distance      Post-Early Stage Diagnosis 
 
*Unmeasured confounder includes income, insurance, and education 
 
CAPTION: Directed Acyclic Graph (DAG) assessing the relationship between distance to a 
testing site and post-early stage diagnosis, accounting for measured and unmeasured 
confounders.   
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CHAPTER FIVE: ONGOING HIV TRANSMISSION AND THE HIV CARE 
CONTINUUM IN NORTH CAROLINA 
 
Abstract: 
Objective: HIV transmission is influenced by status awareness and receipt of care and treatment. 
We analyzed these attributes of named partners of persons with acute HIV infection (index AHI 
cases) to characterize the transmission landscape in North Carolina (NC). Design: Secondary 
analysis of programmatic data. Methods: We used data from the NC Screening and Tracing of 
Active Transmission Program (2002-2013) to determine HIV status (uninfected, AHI, or chronic 
HIV infection [CHI]), diagnosis status (new or previously-diagnosed), and care and treatment 
status (not in care, in care and not on treatment, in care and on treatment) of index AHI cases' 
named partners. We developed an algorithm identifying the most likely transmission source 
among known HIV-infected partners to estimate the proportion of transmissions arising from 
contact with persons at different HIV continuum stages. We conducted a complementary 
analysis among a subset of index AHI cases and partners with phylogenetically-linked viruses. 
Results: Overall, 358 index AHI cases named 932 partners, of which 218 were found to be HIV-
infected (162 (74.3%) previously-diagnosed, 11 (5.0%) new AHI, 45 (20.6%) new CHI).  Most 
transmission events appeared attributable to previously-diagnosed partners (77.4%, 95% 
confidence interval 69.4-85.3%). Among these previously-diagnosed partners, 23.2% (14.0-
32.3%) were reported as in care and on treatment near the index AHI case diagnosis date. In the 
subset study of 33 phylogenetically-linked cases and partners, 60.6% of partners were previously 
diagnosed (43.9-77.3%). Conclusions: A substantial proportion of HIV transmission in this 
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 setting appears attributable to contact with previously-diagnosed partners, reinforcing the need 
for improved engagement in care after diagnosis. 
Introduction: 
Antiretroviral treatment (ART) reduces the probability of HIV transmission by 
suppressing plasma viral load (VL) to undetectable levels.
1,2,78
 However, current estimates of the 
HIV care continuum, or cascade, indicate that most HIV-infected persons in the US are not 
achieving viral suppression. 
8,154
 Undiagnosed persons and those diagnosed but not in care, on 
treatment, and virally suppressed, are potential sources of ongoing transmission and high-priority 
targets for maximizing HIV prevention.  
Current estimates of the transmission contributions made by persons aware and unaware 
of their HIV status are based on mathematical models.
10,11,43
 Empirical estimates to compare to 
modeling studies are difficult to obtain, as they require information at the time of HIV 
acquisition about newly infected persons’ transmitting partners. However, few people are 
diagnosed near the time of HIV transmission,
100,104,126,155-157
 and many do not know with 
certainty from whom they acquired HIV.  
The North Carolina (NC) Screening and Tracing of Active Transmission (STAT) 
program has detected persons with acute HIV infection (AHI) since 2002, providing a unique 
opportunity to characterize the partners of newly infected persons near the time of 
transmission.
100,127
  The primary objective of this secondary analysis of STAT data is to classify 
the HIV status and diagnosis, care, treatment, and viral suppression status of a) all traceable 
partners and b) the most likely transmission source among identified HIV-infected partners for 
acutely-infected persons (index AHI cases) diagnosed in NC between 2002 and 2013. The first 
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analysis characterizes the overall continuum-related landscape in a network where HIV 
incidence is known to be actively occurring; the second describes the continuum attributes of 
persons specifically deemed the most likely transmission source for incident cases. The 
overarching goal of this analysis is to provide information for designing, modeling, and targeting 
HIV care and treatment services.  
Methods: 
For each index AHI case aged ≥16 years and diagnosed between November 2002 and 
June 2013 in NC, we assessed the HIV status and diagnosis, care, and treatment status (if 
available) of sexual and needle-sharing partners he/she named at the time of diagnosis. Data for 
the main analyses originated from the STAT program, a NC Division of Public Health (DPH) 
effort to identify persons with AHI.  In a complementary analysis, we used data from the Center 
for HIV/AIDS Vaccine Immunology 001 Study: Acute HIV Infection Prospective Cohort Study 
(CHAVI-001), an observational study examining factors related to HIV transmission.
128
   
STAT Program 
The STAT program identifies index AHI cases through testing at health departments and 
in community settings (e.g. private providers).
100,127
 AHI is defined as: a) a negative or 
indeterminate antibody test and reproducibly detectable HIV RNA, or b) a positive antibody test 
with seronegative documentation within 30 days. 
Disease intervention specialists (DIS) contact index AHI cases within 72 hours of release 
of HIV test results and perform an initial interview, conduct confirmatory HIV testing, and make 
referrals to HIV care providers. DIS also attempt to find, counsel, and provide HIV testing for all 
named partners during the 8 weeks prior to the index AHI case’s diagnosis date. Before 2012, the 
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NC DPH required index AHI cases to sign a Health Insurance Portability and Accountability Act 
form for DIS to report detailed demographic and testing information about named partners for 
the STAT program.   
Partner HIV Status Determination  
All partners were classified as identifiable or anonymous. Anonymous partners were not 
pursued by DIS because identifying information provided by the index AHI case was absent or 
incomplete. For identifiable partners, the index AHI case provided enough information for DIS 
to identify the partner and classify him/her as “previously-diagnosed” or “undiagnosed” based on 
a search of electronic HIV surveillance databases. Undiagnosed partners who were not located or 
not willing to be tested were classified as “Unknown.” The remaining undiagnosed partners were 
tested for HIV and classified as “HIV-uninfected,” “New AHI,” or “New chronic HIV infection 
(CHI).” For all HIV-infected partners not diagnosed with AHI or AIDS within 6 months of the 
index AHI case diagnosis, results of the Serologic Testing Algorithm for Recent HIV 
Seroconversion (STARHS) were used (when available) to approximate recent (≤6 months) and 
longstanding (>6 months) infection at the time of transmission, based on a normalized optical 
density cut-point of <0.8 on the BED assay.
17
  
Partner Diagnosis, Care, Treatment, and Viral Suppression Status 
Per STAT program protocol, DIS investigate care-seeking and treatment behaviors of 
previously-diagnosed partners in the 6 months before the index AHI case’s diagnosis for 
classification as “in care” (HIV provider-confirmed visit and/or 1 clinical lab present in 
surveillance databases) and/or “on ART” (HIV provider-confirmed receipt of ART and/or a VL 
below the detectable limits of the reported test in surveillance databases).  
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We classified the diagnosis status (new AHI, new CHI, or previously-diagnosed) of all 
HIV-infected partners and the reported care and treatment status at the time of the index AHI 
case diagnosis (not in care, in care and not on ART, in care and on ART, unclassified care and 
treatment) of all previously-diagnosed partners. Because quantitative VLs are not collected as 
part of the STAT program, we extracted all partner VLs reported in the NC electronic HIV/AIDS 
reporting system between 6 months before to 2 months after the index AHI case diagnosis date. 
To assess viral suppression (<200 copies/ml) status near transmission, we considered only the 
closest VL to the index AHI case’s diagnosis date. For previously-diagnosed partners with VLs 
before and after the index AHI case diagnosis date, the closest VL before diagnosis was used to 
assess viral suppression near transmission. 
Likely Transmission Source Identification 
Each index AHI case was classified according to the HIV status pattern of named 
partners (first four columns of Table 5.1): A) the HIV status of all partners was known and only 
one was HIV-infected, B) >1 HIV-infected partner (with or without additional 
unknown/anonymous partners) or one HIV-infected partner with additional unknown/anonymous 
partners, C) only partners of unknown/anonymous status, and D) no HIV-infected or 
unknown/anonymous partners.  
For index cases naming only 1 HIV-infected partner with the status of all other partners 
known (Type A), this single HIV-infected partner was assumed to be the most likely transmitting 
partner. For index AHI cases naming >1 potential transmitting partner (i.e., known HIV-infected 
or status-unknown partner) with at least one confirmed HIV-infected partner (Type B), we 
assumed that the likely transmitting partner was among those partners named. We repeatedly, 
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randomly sampled the known HIV-infected partners 1000 times with replacement to identify the 
most likely transmitting partner. For index AHI cases naming 1 HIV-infected partner (Type B2), 
the probability of selecting that partner was 1, while the probability of selection for each partner 
of index AHI cases naming >1 HIV-infected partner (Types B1, B3) was 1/(number of named 
HIV-infected partners). Index AHI cases not naming any HIV-infected partner (Types C and D) 
were excluded from these analyses. For these cases, the diagnosis, care and treatment status for 
the most likely transmission source among identified partners could not be estimated because all 
partners were HIV-uninfected or of unknown status.  
HIV Care Continuum Analyses 
To describe the overall transmission landscape in this network, we calculated the 
proportion of all HIV-infected partners with each diagnosis, care, and treatment status.  To 
describe the putative transmission contributions of the various continuum stages, we calculated 
these proportions only among the persons identified as the most likely transmission source for 
each incident case. Although no single sample from our repeated sampling approach captures all 
transmitting partners, the combination of the samples provides a reasonable estimate of the range 
of plausible values for the diagnosis, care, and treatment status of the most-likely transmitting 
partner among named HIV-infected partners.
140
   
CHAVI-001 
Between 2006 and 2011, all index AHI cases identified via the STAT program were 
referred for evaluation at the University of North Carolina at Chapel Hill (UNC-CH) or Duke 
University, and offered enrollment in CHAVI-001. Study investigators collected basic 
demographics for each enrolled index AHI case (representing a subset of the STAT index AHI 
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cohort) and data for all partners within 12 weeks of their diagnosis date. Locatable partners were 
offered enrollment in CHAVI-001, regardless of HIV status.  
Upon enrollment, cell-free plasma was extracted from samples provided by index AHI 
cases and HIV-infected partners to isolate viral RNA using the QIAMP Viral RNA Mini Kit 
(Qiagen). DNA sequence alignments, phylogenetic tree generation, and transmission pair 
confirmation were performed on either full length env genes resulting from single genome 
amplification or pro-pol amplicons derived from bulk sequencing as previously described.
129-138
 
The donor was distinguished from the recipient among all phylogenetically-linked transmission 
pairs, using Bayesian Evolutionary Analysis by Sampling Trees (BEAST) v.1.4.8, as previously 
described.
129,139
  
CHAVI-001 Data Analysis 
The HIV status of partners named by index AHI cases enrolled in CHAVI-001 was 
assigned based on CHAVI-001 field investigation and the proportion of phylogenetically-linked 
partners with each diagnosis status was estimated. We based treatment status of 
phylogenetically-linked partners on reported ART history collected at enrollment. Partner care 
status was not collected for study purposes and therefore not assigned. Data from the STAT 
program could not be linked to CHAVI-001 partners for reasons of confidentiality. 
All statistical analyses were conducted in SAS version 9.3 (Cary, NC). The study was 
approved by the UNC-CH Institutional Review Board.  
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Results: 
STAT 
Index AHI cases 
Between November 2002 and June 2013, 358 index AHI cases were identified via the 
STAT program. Index AHI cases were predominantly Black (70.1%), male (83.0%) and self-
identified as men who have sex with men (MSM) (66.5%). Nearly one-quarter of cases had been 
diagnosed with a sexually transmitted infection within 2 month of their AHI diagnosis (24.3%) 
[Table 5.2]. 
Partner Overview 
Overall, 932 sexual partners (4 of whom were also needle-sharing) were reported by 
index AHI cases in the 8 weeks prior to their diagnosis (per-index median=2; range 0-27). Index 
AHI cases provided detailed information for 656 partners (70.4%) as part of the STAT program 
[Figure 5.1a].  Most partners with detailed information were male (85.8%) and Black (62.7%), 
with a median age of 28 years (IQR 23-37) [Table 5.2].  
Of the 656 partners with detailed information, 218 (33.3%) were HIV-infected. Of these, 
162 (74.3%) were previously-diagnosed and 56 (25.7%) were newly-diagnosed (11 AHI and 45 
CHI). An additional 210 partners (32.1%) were HIV-uninfected (antibody and HIV RNA 
negative) at DIS follow-up. The HIV status for 228 partners (34.8%) remained undetermined 
after the DIS investigation (78 anonymous, 31 counseling-and-testing refusals, 48 testing-only 
refusals, 71 unlocatable or unclassified based on DIS reports) [Figure 5.1a].   
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Recent HIV infection could be assessed for 171 (82.6%) HIV-infected partners not 
diagnosed during AHI (145 previously-diagnosed and 26 newly-diagnosed). Ten (38.5%) new 
diagnoses and 8 (5.5%) partners previously-diagnosed in the 6 months before the index AHI case 
had STARHS testing indicative of recent HIV infection at the time of their diagnosis. Only 3 
(37.5%) of the 8 previously-diagnosed, recently-infected partners had entered care between their 
diagnosis and the index AHI case diagnosis; one had initiated ART. Including new AHI 
diagnoses, a total of 29 (13.3%) HIV-infected partners were estimated to have been infected 
within 1 year of the index AHI case.   
Among all 162 previously-diagnosed partners, 26 (16.0%) were not in care, 51 (31.5%) 
were in care but not on ART, and 48 (29.6%) were in care and on ART at the time of the index 
AHI case diagnosis [first bar of Figure 5.2/Supplemental Table A3.1]. Care and treatment status 
was left undetermined after DIS investigation for the remaining 37 (22.8%) previously-
diagnosed partners.  
Overall, 40 (18.3%) previously-diagnosed partners had a VL reported in a NC 
surveillance database 6 months before to 2 months after the index AHI case diagnosis; 19 
(33.9%) newly-diagnosed partners had a VL in the 2 months after the index AHI case diagnosis. 
An additional 31 (14.2%) partners had a VL reported more than 6 months before the index AHI 
case diagnosis, suggesting potential loss from care. The partners’ median VL near the time of the 
index AHI case diagnosis was higher in newly-diagnosed (55,698 copies/ml [range 1,521-
10,000,000]) as compared to previously-diagnosed partners (27,153 copies/ml [range 19-
3,402,708]) [Figure 5.3]. Among the 40 previously-diagnosed partners in care and with an 
available VL, 30 (75.0%) were unsuppressed in the period 6 months before to 2 months after the 
index AHI case diagnosis. Of the 10 virally suppressed partners at the time of their most recent 
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VL, 4 had detectable VLs in the year surrounding the index AHI case diagnosis, indicating 
unsustained suppression.   
Likely Transmitting Partner Estimates 
A total of 106 index AHI cases named only 1 potential HIV-infected transmitting partner 
with all other partners testing negative (Type A), 68 named >1 potential transmitting partner with 
at least one confirmed HIV-infected partner  (Type B), and 127 named only potential 
transmitting partners of unknown status (Type C). The remaining index AHI cases either did not 
name any partners during the 8 weeks prior to their diagnosis (N=38) or only named HIV-
uninfected partners (N=19) (Type D) [Table 5.1].  
Among index AHI cases naming only one HIV-infected partner with all other partners 
testing negative (Type A), over three-quarters of transmission events appeared attributable to 
contact with previously-diagnosed partners (77.4%, 95% confidence interval (CI) 69.4-85.3%) 
[2
nd
 bar of Figure 5.2/Supplemental Table A3.1]. Among previously-diagnosed partners (N=82), 
the proportion of partners reportedly not in care (23.2%, 95% CI 14.0-32.3%), in care and not on 
ART (26.8%, 95% CI 17.2-36.4%), in care and on ART (23.2%, 95% CI 14.0-32.3%), and with 
unclassified care/treatment status (26.8%, 95% CI 17.2-36.4%) were roughly equivalent. Of the 
38 previously-diagnosed partners with a VL near the time of the index AHI case diagnosis, 
94.7% were unsuppressed (N=36, 95% CI 87.6-100.0%)  
Repeated sampling methods resulted in similar diagnosis, care, and treatment status 
estimates among index AHI cases naming >1 potential transmitting partner with at least one 
confirmed HIV-infected partner (Type B) [3
rd
 bar of Figure 5.2/Supplemental Table A3.1] and 
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when combining these  two groups (Types A and B) [4th bar of Figure 5.2/Supplemental Table 
A3.1].  
CHAVI-001 
Overall, 55.5% (N=117) of all index AHI cases identified by the STAT program between 
May 2006 and December 2011 enrolled in CHAVI-001 and were considered in the 
complementary analysis [Table 5.2]. As observed by the STAT program, most index AHI cases 
were male (87.2%), Black (65.0%) and young (median age=25 years, IQR 21-36).  
Index AHI cases reported 367 partners as a part of the CHAVI-001 investigation (per-
index median=3; range 0-14), of whom 119 (32.4%) were HIV-infected. Compared to STAT 
investigations, a smaller proportion of HIV-infected partners identified via the CHAVI-001 study 
were previously-diagnosed (82 (68.9%) previously-diagnosed, 26 (21.8%) new CHI, and 11 
(9.2%) new AHI) [Figure 5.1b]. An additional 126 (34.3%) partners were HIV-uninfected. The 
status of 122 (33.2%) partners remained unknown (78 anonymous, 44 unlocated or refused 
testing). Demographics of partners reported during the CHAVI-001 investigation were similar to 
those observed by the STAT program [Table 5.2]. Seventy (59.8%) index AHI cases named ≥1 
HIV-infected partner; only 47 index AHI cases had ≥1 HIV-infected partner enroll on study and 
provide samples for phylogenetic analysis. The transmitting partner for 33 (70.2%) of these 
index AHI cases was phylogenetically verified. One additional phylogenetic linkage was 
identified between 2 index AHI cases diagnosed 2 years apart. Because neither index AHI case 
named the other during the CHAVI-001 investigation, we could not rule out a shared or 
intermediary transmitting partner and excluded this pair from further analysis. 
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Most of the 33 partners phylogenetically-linked to index AHI cases in CHAVI-001 had 
been previously-diagnosed (60.6%, 95% CI 43.9-77.3%) [4
th
 bar in Figure 5.2/Supplemental 
Table A3.1], although the contribution is smaller than observed in STAT data. Three linkages 
were attributable to AHI–to-AHI transmission (9.1%, 95% CI 0.0%-18.9%). All 
phylogenetically-linked partners were unsuppressed. The median VL of linked partners at 
transmission was 123,928 copies/ml (range 123,928-2,346,147) for new AHI partners, 62,493 
copies/ml (range 2,771-148,042) for new CHI partners, and 72,084 copies/ml (range 10,957-
507,795) for previously-diagnosed partners. Although two phylogenetically-linked partners with 
recognized infection reported a history of ART, neither were on treatment at the time of the 
index AHI case diagnosis. One partner stopped treatment within 1 month of contact with the 
index AHI case.  
Discussion: 
Most observed transmission events in North Carolina appear attributable to contact with 
previously-diagnosed partners. Roughly one-quarter of these previously-diagnosed partners were 
reported to be in care and on ART in the 6 months before the index AHI case diagnosis. 
However, only a small proportion of transmission events were estimated to be a result of 
previously-diagnosed partners confirmed to be virally suppressed. 
These transmission events occur because many previously-diagnosed persons continue to 
engage in high-risk behaviors with uninfected persons, as seen in our analyses of the 
transmission landscape incorporating all identified partners. Over one-third of these identifiable 
partners were HIV-infected; most were aware of their status prior to the index AHI case 
diagnosis. Consistent condom use was reported with only 16.7% of previously-diagnosed 
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partners (data not shown). Moreover, previously-diagnosed partners were uncommonly on 
treatment at the time of contact with the index AHI case, increasing the likelihood of onward 
transmission.
158,159
 In line with observed HIV infection trends in the South,
18,160-162
 these active 
transmission networks, as represented by index AHI cases and their partners, were 
disproportionately populated by young, Black MSM. Engaging this population in care and 
ensuring receipt of ART is certain to lessen the disease burden in these high-prevalence settings. 
The relative contribution of previously undiagnosed partners to onward transmission in 
this study was lower than estimated in other settings. Model-based estimates predicted 50-75% 
of all new HIV infections are due to  partners unaware of their infection,
10,11,43
 which is 
approximately 10-50% higher than the 22%-38% estimates we obtained in this study. 
Our empirical work is limited by a distinct set of biases related to difficult-to-verify 
assumptions and missing information, as compared to modeling studies.  Perhaps most 
importantly, we had phylogenetic analyses on only a small proportion of the population. The 
transmission source cannot be verified in partnerships where phylogenetic testing was not done, 
even if the status of all partners was known and only one was HIV-infected. Furthermore, 
approximately half of the index AHI cohort named at least one status-unknown or anonymous 
partner, and over one-third named only unknown/anonymous partners. Undoubtedly, some 
unknown/anonymous partners transmitted HIV. Status-unknown partners have no record of a 
positive test in NC surveillance databases under the name provided by the index AHI case and 
either refused HIV testing or could not be located. HIV infection may be more prevalent among 
persons refusing HIV testing.
163
 If HIV-infected, status-unknown partners are undiagnosed, 
misnamed by the index AHI case, or were diagnosed outside NC. Anonymous partners did not 
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have any identifiable information, and may be more likely to engage in riskier behaviors and less 
likely to test for HIV or enter care than identifiable partners.  
Partner services for index AHI cases identified by the STAT program occur close to the 
transmission event, decreasing the likelihood of recall bias and increasing the accuracy in 
naming potential transmitting partners and assessing their diagnosis, care, and treatment status. 
However, diagnosis during AHI is relatively uncommon in NC,
63
 making it difficult to assess 
any heterogeneity in partner continuum stages that might have existed over the 11 years under 
analysis. 
The contribution of AHI to ongoing transmission is not easily assessed with these data. 
The duration of AHI is short and partners transmitting during this stage may not be tested until 
they reach CHI. Approximately one-third of newly-diagnosed partners with available STARHS 
testing data were classified as having recent infection, suggesting these partners were unaware of 
their HIV status for a short period of time, with some potentially representing AHI-to-AHI 
transmission. When both the index case and the partner are diagnosed with AHI, the direction of 
transmission is difficult to determine, even if phylogenetically linked,
139
 leaving open the 
possibility that the index AHI case transmitted disease to at least some newly-diagnosed partners 
unaware of their HIV status. 
Partner viral suppression status at the time of transmission is difficult to assign. Only half 
of the previously-diagnosed partners had an available VL in surveillance databases near the time 
of the index AHI case diagnosis and approximately 20% of these partners were virally 
suppressed. The relatively low levels of viral suppression observed among previously-diagnosed 
partners may be a result of more restrictive treatment guidelines in place prior to 2009.
67
 If 
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partners are truly virally suppressed, HIV transmission is known to be unlikely.
1,164
 Sexually 
transmitted co-infection, treatment non-adherence or resistance provide possible explanations for 
potential rebound in virus in the period between the last suppressed VL and contact with the 
index case.
165-167
  
Engagement (and re-engagement) in care and early initiation of treatment should remain 
a high priority to prevent HIV transmission. In both surveillance data from the STAT program 
and phylogenetic data collected via the CHAVI-001 study, a substantial proportion of HIV 
transmission appears attributable to contact with previously-diagnosed partners. Interventions to 
find previously-diagnosed persons not in care and facilitate receipt of consistent care and 
immediate treatment should have a tremendous impact on improving health and reducing HIV 
incidence in this and similar settings.    
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Tables and Figures 
Table 5.1. Index AHI cases by pattern of partner HIV status 
Type Number of 
known HIV-
infected 
partners 
Number of 
known HIV-
uninfected 
partners 
Number of 
unknown status 
partners 
Number of index 
AHI cases with 
partner HIV status 
pattern 
N % 
A 1 ≥0 0 106 (29.6) 
B    68 (19.0) 
  B1 >1 ≥0 0 12 (3.4) 
  B2 1 ≥0 ≥1 38 (10.6) 
  B3 >1 ≥0 ≥1 18 (5.0) 
C 0 0 ≥1 127 (35.5) 
D    57 (15.9) 
  D1 0 0 0 38 (10.6) 
  D2 0 ≥1 0 19 (5.3) 
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Table 5.2. Demographics of Index AHI and Named Partners 
 STAT Program* 
(Inclusive of CHAVI cases) 
CHAVI-001** 
 Index AHI 
(N=358) 
Named Partners^ 
(N=656) 
Index AHI 
(N=117) 
Named Partners 
(N=367) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Age at Diagnosis 26 (21-36) 28  (23-37) 25 (21-36) 27  (22-35) 
Number of Named Partners 2 (1-3) -- -- 3 (2-4) -- -- 
 N (%) N (%) N (%) N (%) 
Reporting Location         
State Laboratory (NAAT Pooling) 255 (71.2) -- -- -- 
-- 
-- 
-- 
-- -- 
Community Setting 103 (28.8) -- -- -- -- 
Gender         
Female 61 (17.0) 85  (13.0) 15 (12.8) 40 (10.9) 
Male 297 (83.0) 563  (85.8) 102 (87.2) 326 (88.8) 
Sex Risk         
Female 61 (17.0) 85 (13.0) 15 (12.8) 40 (10.9) 
Heterosexual Male 39 (10.9) 95 (14.5) 13 (11.1) 26 (7.1) 
MSM 238 (66.5) 468 (71.3) 89 (76.1) 300 (81.7) 
Unknown Risk Male 20 (5.6) -- -- --     --   
Race#         
Black 251 (70.1) 411 (62.7) 76 (65.0) 237 (64.6) 
White, Non-Hispanic 82 (22.9) 160 (24.4) 35 (29.9) 106 (28.9) 
White, Hispanic 20 (5.6) 43  (6.6) 6 (5.2) 8 (2.2) 
Other 3 (0.8) 2  (0.3) --    -- -- -- 
STI in 8 weeks prior to AHI Diagnosis         
Yes 87 (24.3) -- -- 20 (17.1) -- -- 
No 271 (75.7) -- -- 97 (82.9) -- -- 
 *The North Carolina Screening and Tracing of Active Transmission Program 
** Center for HIV/AIDS Vaccine Immunology 001 Study: Acute HIV Infection Prospective Cohort Study 
^ 932 partners were named by Index AHI cases during the STAT investigation. Index AHI cases refused to provide detailed demographic information  
for the STAT Program for a total of 276 partners, leaving 656 with detailed demographic information. 
#
Missing Race not included in table. 
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Figure 5.1 HIV Status of sexual and needle-sharing partners reported by index AHI cases  
A. STAT 
 
 
 
 
 
 
B: CHAVI-001
 
^ 932 partners were named by Index AHI cases during the STAT investigation. Index AHI refused to provide detailed testing information for the STAT Program 
on a total of 276 partners, leaving 656 with detailed demographic information. 
*STAT “Unknown” status includes 31 (20.7%) refusing counselling and testing, 48 (32.0%) refusing testing only, 61 (40.7%) unable to locate and 10 (6.7%) 
who could not be classified. Reason for unknown status could not be identified among CHAVI-001 partners. 
367 Total Partners 
78 Anonymous  
290 Initiated 
119 HIV-infected 
37 Tested Positive 
11 AHI 
26 CHI 
82 Previously-diagnosed 
126 HIV-uninfected 
44 Unknown Status* 
932 Total Partners 
276^  
No details provided 
for DIS Investigation 
47 No Demographics 
or HIV Status 
Classification 
229 Anonymous          
(no demographics) 
656  
Details provided for   
DIS Investigation    
578 Initiated 
Investigation 
218 HIV-infected 
56 Tested Positive 
11 AHI 
45 CHI 
162 Previously-
diagnosed 
210 HIV-uninfected 
150 Unknown Status* 
78 Anonymous        
(with demographics) 
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CAPTION: Figure 5.1A displays the HIV status of partners of index AHI cases identified via the STAT program between November 
2002 and June 2013. Figure 5.1B displays the HIV status of partners reported by index AHI cases enrolled in CHAVI-001  between 
May 2006 and June 2011.  
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Figure 5.2:  Diagnosis, care, and treatment status for HIV-infected partners 
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CAPTION: In Figure 5.2, the diagnosis, care, and treatment status are presented for 1) all HIV-infected partners named by the index AHI cohort 
and identified by the STAT program, 2) the most likely transmission source among identified HIV-infected partners presented by the pattern of 
HIV-infected, uninfected, and status-unknown partners reported to the STAT program and 3) phlyogenetically-linked partners identified via 
the CHAVI-001 study. For estimates of the most likely transmission source where >1 potential transmitting partner was named, repeated random 
sampling was used to estimate diagnosis, care, and treatment status of the partner. NOTE: Potential transmitting partner refers to any partner 
reported in the 8 week period prior to the index AHI diagnosis date who was not classified as HIV-uninfected (e.g. HIV-infected and status-
unknown partners). NOTE: Potential transmitting partner refers to any partner reported in the 8 week period prior to the index AHI diagnosis date 
who was not classified as HIV-uninfected (i.e. HIV-infected and status-unknown partners). 
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Figure 5.3 HIV-infected partner viral load (VL) at the time of the Index AHI case diagnosis by diagnosis status.   
 
 
CAPTION: Figure 5.3 displays the closest VL within 6 months before to 2 months after the index AHI diagnosis date extracted from 
NC surveillance databases for HIV-infected partners and dichotomized by status-unaware versus status-aware partners. 
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CHAPTER SIX: SPATIAL AND TEMPORAL PATTERNS OF EARLY AND LATE HIV 
DIAGNOSES IN NORTH CAROLINA FROM 2005 TO 2013 
 
Abstract: 
Background: HIV test-seeking behaviors may be a function of both time and space. We 
assessed spatial patterns of high rate HIV diagnoses in North Carolina (NC) both before and after 
the adoption of the CDC’s recommendations for routine testing. Methods: Using surveillance 
data from a 52-county region in central NC, we mapped diagnosis rates by disease stage (early 
HIV infection [EHI], chronic HIV infection [CHI], AIDS) and testing period (2005-2007, 2008-
2010, 2011-2013). Bayesian Maximum Entropy smoothed maps were standardized and the 
percent overlap of the top 10
th
, 25
th
 and 50
th
 percentile of diagnosis rates were assessed. We 
conducted a complementary analysis of census tracts involved in high rate clusters identified via 
SaTScan. Results: Overall, 3216 persons were diagnosed with HIV (1060 (33%) EHI, 1659 
(52%) CHI, and 497 (16%) AIDS) at publicly-funded testing sites [crude rate 60.5 per 100,000 
person-years]. Estimated diagnosis rates were highest prior to opt-out testing (2005-2007). An 
underlying, “core” area for HIV diagnosis was observed across each testing period and disease 
stage, as represented by disproportionately high overlap in the top 25
th
 and 50
th
 percentiles. EHI 
identification has geographically changed over time, as indicated by minimal overlap at high 
diagnosis rates (10
th
 percentile). AIDS diagnoses displayed consistent overlap in the southeastern 
part of the study area. High rate EHI and CHI clusters were concentrated in urban centers. 
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Conclusions: High rate diagnoses appear to be spatially dynamic across time and disease stage, 
suggesting possible shifts in the testing activity and/or the epidemic itself over time. 
Introduction: 
Initiation of antiretroviral therapy (ART) increases the life expectancy of HIV-infected 
persons and reduces the probability of HIV transmission by suppressing plasma viral load (VL) 
to undetectable levels.
1,2,7
 However, late stage HIV diagnoses postpones receipt of care and 
limits treatment effectiveness.
9
 Over one-third of HIV-infected persons in the United States 
receive an AIDS diagnosis within one year of their HIV diagnosis.
9
 In an effort to identify and 
link HIV-infected persons to care earlier during their infection, the Centers for Disease Control 
(CDC) recommended that providers adopt routine, opt-out HIV testing.
14
  
The impact of the CDC’s recommendations for routine, opt-out testing has been 
inconclusive. While acceptability of the recommendations is high,
168,169
 the effectiveness of the 
recommendations in terms of case detection and identification of recent infection have been 
mixed.
52,169-175
 Geography may be a factor in understanding testing behaviors of both providers 
and patients. Persons living in rural areas are less likely to be tested for HIV
12,176
 and more likely 
to test later during the course of their disease than urban residents.
85
 
North Carolina (NC) is representative of the HIV epidemic in the Southeastern United 
States and provides a unique setting to assess stage of HIV at diagnosis. Over the past decade, 
the NC Division of Public Health (DPH) has tracked acute HIV infection (AHI) recent HIV 
infection (RHI) (cases identified within approximately 6 months of infection), and AIDS cases, 
allowing for the classification of stage of disease based on testing results.  
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In this analysis, we aimed to assess spatial clustering of HIV diagnoses by stage of 
disease in NC both before and after the CDC recommended routine, opt-out HIV testing. 
Enhanced understanding of the relationship between residence and the timing of HIV testing 
both before and after the CDC recommendations for routine, opt-out testing provides evidence 
into the effectiveness of these recommendations and identifies the areas in NC that would most 
benefit from additional resources to identify early infection. 
Methods: 
Data Sources 
 We performed a cross-sectional analysis using data collected from 3 different 
surveillance mechanisms at the NC DPH:  Counselling and Testing Report (CTR) data, 
electronic HIV/AIDS Reporting Service (eHARS), and the Screening and Tracing of Active 
Transmission (STAT) Program.   
 A CTR form is completed for all persons requesting a test at a publicly-funded testing 
site in NC to capture personal identifiers, demographics, risk factors, testing site, and residential 
zip code. Data from the CTR form are linked to specific blood samples submitted to the NC state 
laboratory of public health for HIV testing.  
All HIV-positive tests in the CTR system are linked to eHARS, a state-run database that 
maintains demographic, risk factor, and HIV/AIDS diagnosis dates for regular surveillance 
reporting to the CDC. eHARS also collects case addresses at the time of both HIV and AIDS 
diagnosis and Serologic Testing Algorithm for Recent HIV Seroconversion (STARHS) testing 
results.  
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 Since 2002, the STAT program has identified persons diagnosed with acute HIV (AHI) in 
NC through nucleic acid amplification test (NAAT) pooling procedures for all negative HIV 
antibody tests at the state laboratory.
100,177
 The STAT program defines AHI as a negative or 
indeterminate antibody test followed by reproducibly detectable HIV RNA. All persons 
diagnosed with AHI and identified by the STAT program were linked to their case report in 
eHARS for this analysis.  
Study Area 
 We restricted this analysis to a 52-county (1597 census tracts) study area in central North 
Carolina (NC) that represents both urban and rural areas and accounts for approximately 80% of 
all new HIV diagnoses and 74% of the population in the state
178
 [Figure 6.1]. The remaining 48 
NC counties contain a substantial proportion of census tracts with zero-case counts that could 
interfere with the stability of spatial models used to assess clustering of disease. Therefore, cases 
diagnosed in these counties were excluded from our analysis. 
Study Population: 
 We classified cases as any person aged 16 years or older diagnosed at a publicly-funded 
testing site between July 2005 and June 2013 in the 52-county study area.  This represents 
approximately 40% of all new HIV diagnoses in in the study area.  
 To estimate the underlying testing population at a publicly-funded testing site, we 
deduplicated HIV tests reported in the CTR system based on recorded name, date of birth, race, 
gender, and zip code using The Link King Program (version 7.1.21, Camelot Consulting 
Olympia, Washington). This program uses a combination of probabilistic and deterministic 
algorithms to determine linkages.
141
 The sensitivity and positive predictive value of linkages 
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produced by The Link King program have previously been found to be >90%, when using 
reviewers’ decision as the gold standard.141 We used the default program settings in all instances 
except for the following: 1) no minimum disagreement weight was set for zip codes (e.g zip 
codes could be different and the records could still match) and 2) we did not pre-specify the 
minimum weight for probabilistic linkages. 
We generated 2 estimates of the testing population in which we deleted non-exact 
matches (conservative estimate) or kept non-exact matches (liberal estimate) classified to linkage 
certainty categories 4, 6, and 7 by the Link King program. The testing population based on the 
conservative estimate was used to calculate testing rates for this analysis.  
Testing Period: 
We classified both cases and the testing population to a testing period based on both the 
date of their HIV test and estimated date of implementation of the CDC’s recommendations for 
expanded testing. Revised recommendations were made in September 2006.
14
 However, we 
estimated a year lag for statewide implementation and categorized all cases and testers as 
occurring: at or before (Period 1: July 2005- December 2007), immediately after (Period 2: 
January 2008- December 2010), or after with some delay (Period 3: January 2011- June 2013). 
HIV-Stage Assignment: 
 Using a 3-step process, we assigned all new diagnoses a stage of disease at diagnosis 
(AHI, RHI, Chronic HIV Infection (CHI), and AIDS) based on STAT, STARHS, and standard 
HIV testing results. First, STAT cases were linked to eHARS to identify all cases diagnosed with 
AHI. Next, all cases diagnosed with AIDS in eHARS (as defined by either 1) CD4 cell count 
<200 cells/mm
3
, 2) CD4 count < 14 percent of all lymphocytes, or 3) a diagnosis of one or more 
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AIDS-defining illnesses) at the time of or within 6 months of an HIV diagnosis were identified. 
For the remaining cases with STARHS results, we approximated recent (RHI, ≤6 months) from 
longstanding infection (CHI, >6 months) based on a normalized optical density cut-point of <0.8 
on the BED assay.
17
 Non-AHI and non-AIDS cases without available STARHS testing were 
excluded from analysis. Due to the small numbers of AHI diagnoses each year, AHI and RHI 
were combined for the remainder of this analysis and considered as early HIV infection (EHI). 
Geocoding: 
 Residential addresses of all new HIV cases were geocoded to an ESRI (Redlands, 
California)-supplied NC street basemap using ArcGIS (version 10.1, ESRI). Persons with an 
address that could not be geocoded or who did not provide a full address were geocoded to a 
population-weighted, random point in their zip code (if reported). New HIV diagnoses were 
aggregated in space to the tract level and in time by the testing period to preserve confidentiality. 
Cases with residential addresses outside the geographic boundary of the 52-county study area 
were excluded. 
The entire deduplicated testing population at publicly-funded testing sites were also 
geocoded to a population-weighted, randomly-assigned point in the zip code provided on the 
CTR form. If a person reported more than 1 zip code at subsequent testing events, a zip code was 
selected at random for analysis. Geocoded zip codes for persons testing for HIV at publicly-
funded testing sites were then aggregated to estimate the testing population in each census tract.  
Spatial Analysis: 
  To compare disease maps across multiple time periods, we assigned HIV diagnosis rates 
[number of cases tested per tract/(number of people testing in each tract*time)] by stage of 
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disease and testing period to the geographic center (centroid) of each 2010 census tract for 
subsequent analysis, estimation, and mapping. The study area contains 1597 (73.1%) of the 
census tracts in NC in 2010. Some census tract boundaries changed when the results of the 2010 
census were released. A difference in clustering due to these changes was expected to be 
minor.
143
 
Bayesian Maximum Entropy 
Bayesian Maximum Entropy (BME), specifically the uniform model extension of BME 
(UMBME), was used to describe the changes in spatial distribution of HIV diagnosis rates by 
stage of disease in each testing period. In UMBME, measurement error is assumed to be 
distributed uniformly around the observed rate in an interval the size of 1/testing population.
144
 
Therefore, observed diagnosis rates are treated as probabilistic (“soft”) data with measures of 
uncertainty as defined by the uniform distribution interval. BMEGUI (version 3.0.1, Chapel Hill, 
North Carolina), the computer software used to implement the BME approach, was used to 
conduct this composite space-time analyses and mapping.
146
  
Once a smoothed map was created for each of the 3 disease stages during the 3 testing 
periods under consideration, maps were normalized to the same scale to assess percent overlap of 
high diagnosis rate areas. A cut-off point at the highest 10
th
 percentile on this normalized scale 
was used to dichotomize diagnosis rates in each pixel as high versus low rates. The proportion of 
“high rate” pixels on one map that were also “high rate” on another map was assessed for each 
disease stage-time period combination. We varied the cut-off point used to define “high-rate” 
clusters to the top 25
th
 and 50
th
 percentiles in sensitivity analyses.  
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Cluster Detection: 
In a complementary analysis, the Kulldorff spatial scan statistic (SaTScan software, 
Information Management Services, Inc., Silver Spring, Maryland) was applied to identify the 
presence and location of clusters by disease stage and testing period using crude census tract 
diagnosis rates. High-rate clusters were identified as areas where the observed number of cases 
was greater than the expected number of cases based on spatial randomness. A likelihood ratio 
test statistic was calculated for each potential cluster and p-values corresponding to the test 
statistic were calculated using Monte-Carlo simulation. The percent overlap of census tracts 
involved in high-rate clusters identified via the Kuldorff spatial scan test statistic by disease 
stage-time period categories was calculated, as described in the BME analysis.  
The study was approved by the University of North Carolina at Chapel Hill Institutional 
Review Board. 
Results: 
Between July 2005 and June 2013, 1,620,781 samples were tested for HIV at publicly-
funded testing sites in NC. After deduplication using a conservative linking definition, 853,900 
unique persons were tested for HIV. A total of 664,695 (77.8%) of this testing population 
reported a zip code within the 52-county study area and could be geocoded.  
A total of 10,690 persons had a positive HIV test reported to the NC DPH during this 
period in the study area, with 4893 (45.77%) testing in publicly-funded testing sites. Previous 
diagnoses (N=763), persons <16 years of age (N=14), and persons whose reported address at the 
time of HIV diagnosis was a correctional facility (N=90) were excluded. Of the 4023 remaining 
cases, 3621 (90.0%) were geocoded to the address provided at the time of HIV diagnosis.  An 
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additional 388 cases could be geocoded to a random location within the provided zip code, 
resulting in a total of 4009 (99.7%) cases whose residential address or zip code at the time of 
HIV testing was geocoded. Of these, 3216 (80.2%) had enough information to classify disease 
stage at diagnosis (RHI, CHI, or AIDS), representing the study population for this analysis. 
Of the 3216 newly-infected cases, most were male (76.4%), black (70.4%), and self-
identified as a man who has sex with men (MSM) (53.2%).  The median age of participants was 
29 years (IQR 23-41). HIV diagnoses occurred most often in HIV counselling sites (72.0%). The 
HIV testing population was less likely to male (37.6%), black (44.2%), or MSM (2.9%) [Table 
6.1]. Using testing results reported to the NC DPH, participants could be classified by stage of 
disease at diagnosis: 1060 (33%) EHI (156 AHI and 904 RHI), 1659 (51.6%) CHI, and 497 
(15.5%) AIDS cases [Table 6.1].  
The overall crude HIV testing rate in the study area was 60.5 cases per 100,000 person-
years. The rate varied by stage of disease: 19.9 EHI cases, 31.2 CHI cases, and 9.3 AIDS cases 
per 100,000 person-years. Given the exclusions we used to define our study population, this is 
likely an underestimate of the true diagnosis rates in this area. The individual census tract crude 
HIV diagnosis rates ranged from 0 to 3571.4 cases per 100,000 person-years, with over one-third 
of the tracts with a rate of zero (N=565; 35.4%). When we removed the spatial mean trend for 
covariance modeling and BME estimation, rates were more normally distributed for each disease 
stage. 
UMBME Analysis 
The covariance plots used in UMBME estimation suggest that the diagnosis rates for 
EHI, CHI, and AIDS in the study area exhibit differing levels of spatial dependence 
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[Supplemental Figure A4.1]. The spatial range for CHI cases was longer than that of both EHI 
and AIDS cases (4 km for CHI versus 1 km for both EHI and AIDS). While relatively short (1 
km), the spatial range for AIDS cases is not entirely smooth, suggesting potential movement in 
space after infection but before diagnosis. The temporal lag for each disease stage was long (6 
years for EHI and CHI; 2.5 years for AIDS). 
UMBME estimated diagnosis rates were highest during Period 1 (2005-2007) when opt-
out testing was not yet adopted [Table 6.2]. However, the absolute number of cases identified 
was lowest during this period. Diagnosis rates during CHI were highest across all 3 periods 
compared to other disease stages. The lowest diagnosis rates were observed among AIDS cases 
during each of the testing periods. An increase in diagnosis rates from Period 2 (2008-2010) to 
Period 3 (2011-2013) was observed for both EHI and AIDS diagnoses. However, AIDS 
diagnoses had a larger relative increase from Period 2 (2008-2010) to Period 3 (2011-2013) 
compared to EHI diagnoses. 
Overlap 
Relatively little overlap at the highest rates (top 10 percentile) was observed across 
disease stage and time period [Table 6.3a and b/Figure 6.2/Supplemental Figure A4.2 and A4.3]. 
However, disproportionately higher amounts of overlap at lower rates (top 25 and top 50 
percentiles) were observed by disease stage and testing period, suggestive of an underlying core 
area of HIV diagnosis, and consequently, transmission in central NC. 
The overlap of EHI and CHI diagnoses at the highest rates (top 10 percentile) was 
relatively constant in terms of both quantity and location [Table 6.3a/Figure 6.2/Supplemental 
Figure A4.2]. Between Period 1 (2005-2007) and Period 2 (2008-2010), an increase in the 
 82 
 
number of overlapping high rate (top 10 percentile) areas was observed between CHI and AIDS 
diagnoses, possibly indicating cases that would have been diagnosed during AIDS were being 
found earlier and diagnosed during CHI in these areas. Most of the increase in overlap was 
observed in the southeastern part of the study area.  
 Minimal testing period overlap at the highest rates (top 10 percentile) was observed 
within each disease stage [Table 6.3b/Figure 6.2/Supplemental Figure A4.3]. At lower rates (top 
25 and 50
th
 percentiles), significant overlap was observed providing further evidence for a 
background, “core” area. Overlap of high rate EHI diagnoses across time was spatially dynamic, 
indicating EHI was consistently diagnosed across the study area and the location of high rate 
EHI diagnoses changed over time. Overlap of high rate AIDS diagnoses was highest across all 3 
testing periods [Table 6.3b] and was geographically prominent in the southeastern part of the 
study area.  
Kulldorf Spatial Scan Statistic 
In the complementary analysis, the number of statistically significant (p<0.05) high rate 
clusters identified by the Kulldorff spatial scan statistic varied by disease stage and study period 
[Figure 6.3/Supplemental Table 6.1]. During Period 1 (2005-2007), high rate clusters for each 
disease stage were concentrated in the major urban centers located in the study area. In Period 2 
(2008-2010), the high rate clusters remained in roughly the same location, with several AIDS 
clusters disappearing or shrinking, possibly because these persons were being identified earlier 
during the course of their disease. During Period 3 (2011-2013), a large AIDS cluster was 
identified in the southeastern part of the study area.  
 83 
 
Overlap of census tracts involved in high rate clusters was highest between EHI and CHI 
during all time periods, with Period 2 (2008-2010) displaying the most overlap [Table 6.4a]. 
Overlap of high rate EHI and CHI clusters was only observed in urban centers [Figure 6.3a].  
Across testing periods, CHI clusters displayed the most overlap, which was concentrated 
in urban centers. High rates AIDS clusters displayed the least amount of overlap, with no single 
census tract being involved in high rate clusters across all three time periods [Figure 6.3b/Table 
6.4b].   
Discussion: 
A core HIV diagnosis area was observed across each testing period and disease stage, but 
only at lower diagnosis rates. In these areas, stage of disease does not appear to be heavily 
influenced by location or the adoption of the CDC’s testing recommendations. Areas with high 
rates of HIV diagnosis by disease stage and testing period were more spatially dynamic, with 
minimal overlap observed by disease stage and testing period. This could indicate shifting trends 
in the underlying epidemic in the central NC.  
Recognition of EHI is important to fully realize the benefits of HIV care and treatment 
and to follow trends in active transmission across the study period. In our analysis, EHI 
diagnoses appeared to be clustered in urban centers, with small pockets of high rate EHI in rural 
areas. Areas with high rates of early diagnosis during one testing period were unlikely to 
experience high rates of early testing in a different period in this analysis. This could be due to a 
shift in the epidemic or a change in testing activity (partially explained by the CDC’s 
recommendations for routine, opt-out testing). Due to high levels of infectiousness during EHI, 
improved diagnosis, linkage to care, and initiation of ART in areas with high rates of EHI 
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diagnosis could have a major impact on transmission particularly if the spatial patterns of the 
epidemic truly are shifting in North Carolina. 
High rate EHI/CHI overlap remained relatively constant across all testing periods in 
terms of quantity and location in both the UMBME and SaTScan analyses. This suggests EHI 
and CHI diagnoses occur in comparable risk populations with similar test-seeking behaviors. As 
a result, targeting resources for HIV testing and care to areas with high rates of CHI diagnoses 
may be an effective strategy to identify early stage HIV infection.  
Overlap of high rate AIDS diagnoses across each time period was consistently high and 
concentrated in the southeastern part of the study area. This part of NC represents a rural part of 
the state that is highly impoverished.
179
 Perceived risk, stigma against HIV-infected persons, and 
accessibility may all factor in the HIV test-seeking behaviors of persons living in this part of the 
state.
44
 Alternatively, testing sites in this part of the state may not have fully adopted routine, 
opt-out HIV testing practices, resulting in increased rates of late stage diagnoses.
180
 
 As observed in other settings
169,170,172-175
 the CDC’s recommendations for routine, opt-out 
testing resulted in an increase in the absolute number of HIV-infected persons identified, some of 
whom would have likely been missed under targeted or diagnostic testing approaches. However, 
the number of tests to identify one new positive also increased, resulting in lower overall rates 
after the adoption of the CDC’s recommendations. Early HIV infection diagnosis rates remained 
lower than CHI diagnoses during each testing period, suggesting routine, opt-out testing may not 
be the most effective strategy to identify early HIV over a sustained period of time in this setting.  
 We present a novel method to classify stage of disease based on testing results. Disease 
stage is traditionally based on CD4 cell counts,
181
 which requires a newly-diagnosed person to 
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have contact with the HIV care system and a lab value be reported to the NC DPH. Because care 
reporting standards varied across the study period, we developed a disease stage classification 
algorithm that relied only on testing results collected in eHARS. This algorithm is not without 
bias. The BED assay used for STARHS testing is a nonspecific test, with AIDS diagnoses or 
persons on antiretroviral therapy (ART) sometimes classified as a recent infection.
112,113
 We 
assumed this misclassification was minor since our study population included only newly-
diagnosed persons who were not likely to have a history of ART use and we removed all persons 
diagnosed with AIDS prior to the assignment of recent infection. However, it is possible that the 
observed overlap of high rate EHI and AIDS diagnoses represents some expected 
misclassification. 
UMBME smoothing models provide an accurate prediction of the underlying diagnosis 
rate in an area by effectively imputing disease rates to areas where data are missing. This 
smoothing process can result in the addition of “noise” in the estimated rates.144 Therefore some 
of the high rate areas may be an artifact of the smoothing process used in UMBME estimation. 
To address this, we aggregated cases to the census tract level and three-year testing periods 
because rare diseases, such as HIV, tend to be more spatially correlated when measured over 
larger areas and time periods, improving the smoothing of UMBME models.
144
 However, these 
larger units of aggregations do mask some sub-unit variation and could result in 
misinterpretation of true underlying spatiotemporal patterns.
182
 
Using crude diagnosis rates, the SaTScan cluster analysis identified areas of high 
diagnosis rate clustering in central NC. While we are unable to directly compare the results from 
the SaTScan cluster analysis based on crude census tract rates with the smoothed rates from 
UMBME estimation, both methods are useful tools to assess spatial patterns in diagnosis rates at 
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a local level. Expectedly, we observed some variation the results between the two methods due 
to the use of different diagnosis rates, particularly in the maps of AIDS diagnosis rates. AIDS 
represented the disease stage with the lowest diagnosis rates and therefore the highest variability 
in UMBME estimation, providing some explanation for the observed differences. 
As part of this analysis, we excluded over half of the newly-diagnosed HIV infections to 
assess overall positivity rates for people diagnosed at publicly-funded testing clinics. We also 
excluded an additional 20% of cases whose address could not be geocoded. Therefore, the rates 
presented in this analysis likely underestimate the total diagnosis rates in each census tract. 
However, for the first time in NC, we estimated the underlying testing population at publicly-
funded testing sites, providing information about utilization of health department sponsored HIV 
testing. Focusing our analysis to publicly-funded testing sites illustrates the effectiveness of 
current state and federally-funded testing programs which could inform future allocation of 
public resources.   
In central NC, a definite core area of non-high rate diagnoses was apparent across all 
disease stages and testing periods. Areas of high rate diagnosis by disease stage and testing 
period were more spatially dynamic. Engaging recently-infected persons in care and initiating 
treatment could impact HIV transmission in areas with high rates of EHI diagnoses, while 
interventions emphasizing the importance of early diagnosis may be necessary in areas with 
persistent or re-emerging high rates of AIDS diagnoses. A spatial understanding of test-seeking 
behaviors is an effective tool in developing and targeting future HIV testing and prevention 
interventions.   
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Tables and Figures 
Figure 6.1. Central North Carolina Study Area 
 
CAPTION: 52-county study area in central North Carolina roughly corresponds to the North Carolina 
Division of Public Health Field Services Unit Regions 2 (Charlotte), 3 (Winston-Salem/Greensboro), 4 
(Raleigh), and 5 (Fayetteville).  
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Table 6.1: Demographics of newly-diagnosed cases and testing population in 
Central North Carolina, 2005-2013 
  
Total Cases 
N=3216 
Testing Population* 
N=664,695 
  Median IQR Median IQR 
Age 29 (23-41) 26 (21-35) 
 N % N % 
Stage of Diagnosis       
AHI 156 (4.9) 156 (0.02) 
RHI 904 (28.1) 904 (0.1) 
CHI 1,659 (51.6) 1,659 (0.3) 
AIDS 497 (15.5) 497 (0.1) 
Gender       
Female 759 (23.6) 410,622 (61.8) 
Male 2,457 (76.4) 250,089 (37.6) 
Transgender 0 (0.0) 142 (0.0) 
Race       
Black 2,265 (70.4) 293,718 (44.2) 
White NH 505 (15.7) 189,293 (28.5) 
Hispanic 328 (10.2) 128,886 (19.4) 
Other 117 (3.6) 20,519 (3.1) 
Risk Group       
MSM 1,710 (53.2) 19,166 (2.9) 
IDU 71 (2.2) 7,471 (1.1) 
MSM/IDU 17 (0.5) 833 (0.1) 
Other 470 (14.6) 539,360 (81.1) 
Region       
2: Charlotte 1,045 (32.5) 167,903 (25.3) 
3: Winston-Salem 624 (19.4) 155,015 (23.3) 
4: Raleigh 1,031 (32.1) 187,238 (28.2) 
5: Fayetteville 516 (16.0) 97,609 (14.7) 
Period of Diagnosis*       
2005-2007 1,021 (31.7) 227,236 (34.2) 
2008-2010 1,390 (43.2) 343,552 (51.7) 
2011-2013 805 (25.0) 299,306 (45.0) 
Testing Site       
HIV Counselling and Testing Agency 2,316 (72.0) 32507 (4.9) 
Sexually Transmitted Disease Clinic 217 (6.7) 254,649 (38.3) 
Outpatient Facility 302 (9.4) 220,166 (33.1) 
Other 342 (10.6) 123,984 (18.7) 
*A person could test in each period, therefore numbers do not add up to 100%. 
Note: Missing information not included in table 
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Table 6.2. Median, Minimum, and Maximum UMBME Diagnosis Rates (per 100,000 person-years) by Disease Stage and Testing Period 
  
Testing 
Population* 
EHI CHI AIDS Total 
Period N N Median Range N Median Range N Median Range N Median Range 
P
er
io
d
 1
 
(2
0
0
5
-
2
0
0
7
) 
227,236 320 120.29 
(0.00-
3400.70) 
546 194.78 
(0.00-
6714.60) 
155 49.25 
(0.00-
7512.10) 
1021 358.61 
(0.00-
9076.60) 
P
er
io
d
 2
 
(2
0
0
8
-
2
0
1
0
) 
343,552 439 81.42 
(0.00-
5035.40) 
755 134.34 
(0.00-
6985.30) 
196 24.32 
(0.00-
1903.10) 
1390 238.46 
(0.00-
9785.10) 
P
er
io
d
 3
 
(2
0
1
1
-
2
0
1
3
) 
299,306 301 85.26 
(0.00-
5033.00) 
358 102.24 
(0.00-
4089.70) 
146 37.92 
(0.00-
5020.80) 
805 222.19 
(0.00-
15048.00) 
*Conservative Estimate of Testing Population 
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Table 6.3A. Number and Percent of Overlap of High Rate Disease Stage Pixels by Testing Period: UMBME Estimation  
  
EHI/CHI CHI/AIDS EHI/AIDS EHI/CHI/AIDS 
Testing 
Period 
Percentile N % N % N % N % 
Period 1 
2005-2007 
Top 10% 69 (13.48) 41 (8.01) 112 (21.88) 18 (3.52) 
Top 25% 722 (56.41) 697 (54.45) 852 (66.56) 585 (45.70) 
Top 50% 2136 (83.44) 2178 (85.08) 2169 (84.73) 1981 (77.38) 
Period 2 
2008-2010 
Top 10% 73 (14.26) 99 (19.34) 41 (8.01) 15 (2.93) 
Top 25% 818 (63.91) 674 (52.66) 697 (54.45) 563 (43.98) 
Top 50% 2241 (87.54) 2111 (82.46) 2330 (91.02) 2004 (78.28) 
Period 3 
2011-2013 
Top 10% 73 (14.26) 50 (9.77) 61 (11.91) 9 (1.76) 
Top 25% 575 (44.92) 552 (43.13) 782 (61.09) 447 (34.92) 
Top 50% 1960 (76.56) 2020 (78.91) 2159 (84.34) 1847 (72.15) 
 
Table 6.3B. Number and Percent of Overlap of High Rate Testing Period Pixels by Disease Stage: UMBME Estimation  
  
Period 1 (2005-2007)/ 
Period 2 (2008-2010) 
Period 2 (2008-2010)/ 
Period 3 (2011-2013) 
Period 1 (2005-2007)/ 
Period 3 (2011-2013 
Period 1 (2005-2007)/ 
Period 2 (2008-2010)/ 
Period 3 (2011-2013) 
Disease 
Stage 
Percentile N % N % N % N % 
EHI 
Top 10% 71 (13.9) 72 (14.1) 106 (20.7) 37 (7.2) 
Top 25% 849 (66.3) 880 (68.8) 860 (67.2) 772 (60.3) 
Top 50% 2276 (88.9) 2275 (88.9) 2139 (83.6) 2087 (81.5) 
CHI 
Top 10% 130 (25.4) 95 (18.6) 62 (12.1) 44 (8.6) 
Top 25% 836 (65.3) 601 (47.0) 544 (42.5) 493 (38.5) 
Top 50% 2156 (84.2) 2011 (78.6) 1967 (76.8) 1877 (73.3) 
AIDS 
Top 10% 114 (22.3) 109 (21.3) 103 (20.1) 68 (13.3) 
Top 25% 783 (61.2) 806 (63.0) 951 (74.3) 733 (57.3) 
Top 50% 2398 (93.7) 2413 (94.3) 2462 (96.2) 2326 (90.9) 
*Total Number of Pixels in study area=5120; 10% of Pixels=512, 25% of Pixels=1280, 50% of Pixels=2560 
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NOTE: Table 6A provides estimates of the percent overlap of disease stage (early HIV infection [EHI], chronic HIV infection [CHI], AIDS) 
by percentile of diagnosis rate (top 10, 25, and 50
th
 percentile) during each testing period. Table 6B provides estimates of the percent overlap 
of testing period (2005-2007, 2008-2010, 2011-2013) by percentile of diagnosis rate (top 10, 25, and 50
th
 percentile) within each disease stage 
(EHI, CHI, AIDS). 
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Figure 6.2. Percentiles of UMBME Diagnosis Rates by Stage of Disease and Testing Period 
 EHI CHI AIDS 
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CAPTION: UMBME diagnosis rate estimates by testing period (2005-2007, 2008-2010, 2011-2013) and disease stage (early HIV 
infection [EHI], chronic HIV infection [CHI], and AIDS). Red indicates the top 10 percentile of testing rate, blue corresponds to the 
75-89
th
 percentiles and green corresponds to the 50-74
th
 percentile. The remaining white areas represent the bottom 50
th
 percentile in 
each testing period/disease stage map. 
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Table 6.4a. Overlap of High Rate Disease Stage Clusters by Testing Period detected by Kulldorff’s Spatial Scan Statistic 
 
Census Tracts in High Rate 
Clusters 
Overlap of Census Tracts 
 
EHI CHI AIDS EHI/CHI CHI/AIDS EHI/AIDS EHI/CHI/AIDS 
 
N N N N % N % N % N % 
Period 1 
(2005-
2007) 
207 172 102 134 (8.4) 10 (0.6) 14 (0.9) 5 (0.3) 
Period 2 
(2008-
2010) 
219 264 32 166 (10.4) 27 (1.7) 28 (1.8) 27 (1.7) 
Period 3 
(2011-
2013) 
184 170 149 128 (8.0) 54 (3.4) 37 (2.3) 37 (2.3) 
 
Table 6.4b. Overlap of High Rate Testing Period Clusters by Disease Stage detected by Kulldorff’s Spatial Scan Statistic 
 
Census Tracts in High Rate 
Clusters 
Overlap of Census Tracts 
 
Period 1 
(2005-
2007) 
Period 2 
(2008-
2010) 
Period 3 
(2011-
2013) 
Period 1 (2005-
2007)/ Period 2 
(2008-2010) 
Period 2 (2008-
2010)/ Period 3 
(2011-2013) 
Period 1 (2005-
2007)/ Period 3 
(2011-2013 
Period 1 (2005-
2007)/ Period 2 
(2008-2010)/ 
Period 3 (2011-
2013) 
 
N N N N % N % N % N % 
EHI 207 219 184 119 (7.5) 133 (8.3) 93 (5.8) 66  (4.1) 
CHI 172 264 170 122 (7.6) 145 (9.1) 107 (6.7) 95 (5.9) 
AIDS 102 32 149 3 (0.2) 7 (0.4) 2 (0.1) 0 (0.0) 
*1597 Census Tracts used as denominator 
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NOTE: Table 6.4a provides estimates of the percent overlap of EHI, CHI, and AIDS by testing period. Table 6.4b provides estimates 
of the percent overlap of Period 1: 2005-2007, Period 2: 2008-2010, and Period 3: 2011-2013 by disease stage. 
  
  
 
9
6
 
Figure 6.3a. Overlap of Statistically Significant High Rate Disease Stage Clusters by Testing Period (Kulldorff Spatial Scan Statistic)  
Period 1 (2005-2007) Period 2 (2008-2010) Period 3 (2011-2013) 
   
 
Figure 6.3b. Overlap of Statistically Significant High Rate Testing Period Clusters by Disease Stage (Kulldorff Spatial Scan Statistic)  
EHI CHI AIDS 
   
 
CAPTION: Overlap of census tracts involved in high rate clusters identified by the Kulldorff Spatial Scan Statistic in SaTScan by 
disease stage and testing period. Figure 6.3a displays the overlap of early HIV infection [EHI] (red), chronic HIV infection [CHI] 
(green), and AIDS (blue) by testing period. Figure 6.3b displays the overlap of Period 1: 2005-2007 (red), Period 2: 2008-2010 (blue), 
and Period 3: 2011-2013 (green) by disease stage. 
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CHAPTER SEVEN: TRAVELLING LONGER DISTANCES THAN 
GEOGRAPHICALLY NECESSARY TO A TESTING SITE IS ASSOCIATED WITH 
DELAYS IN HIV DIAGNOSIS 
 
Abstract: 
We assessed the association between post-early-stage HIV disease at diagnosis and 
distance from residence to publicly-funded testing sites in central North Carolina over the period 
2005-2013. Based on HIV testing results collected for surveillance purposes, we identified 1018 
early-stage and 2010 post-early-stage diagnoses. Network distance between reported residence at 
diagnosis and publicly-funded testing sites was calculated. A slightly increased prevalence of 
post-early-stage diagnoses among cases diagnosed at sites that were >5 miles from their 
residence, but lived within 5 miles of a different publicly-funded testing site, was observed when 
adjusted for race/ethnicity and time period (Prevalence Ratio =1.09, 95% Confidence Interval 
1.03-1.16).  
Introduction: 
 Diagnosis and presentation to care during the early stages of HIV have substantial 
individual and public health benefits.
1-5
 Early care and treatment initiation are linked to 
decreased disease-related morbidity, mortality and transmission risk.
1,7
 Despite this, 
approximately 35-45% of HIV-infected persons in the United States are diagnosed late in the 
course of their disease and receive an AIDS diagnosis within one year of their HIV diagnosis.
8
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Inaccessibility of HIV services in one’s community could exacerbate delays in testing.183 
A large proportion of HIV-infected persons in the southeastern United States live in rural areas,
79
 
and tend to test later in the course of their disease than persons living in urban areas.
12
 High 
levels of poverty, distrust in the medical system, and perceived stigma in the community against 
HIV-infected persons living in the South further influences access to HIV services.
31,184
 The 
main goal of this analysis was to describe the geographic-related characteristics of persons newly 
infected with HIV in North Carolina (NC) and assess the relative difference in prevalence of 
post-early-stage disease associated with increased distance from publicly-funded testing sites. 
Methods: 
The associations between later diagnosis and distance to 1) the publicly-funded testing 
site of diagnosis and 2) the closest publicly-funded testing site were examined with cross-
sectional data reported in the NC electronic HIV/AIDS reporting system (eHARS) between July 
2005 and June 2013. These data were collected for surveillance purposes and provide 
information about real-world testing behavior in NC. This study was approved by the University 
of North Carolina at Chapel Hill Institutional Review Board. 
Study Population: 
 We classified cases as any person aged 16 years or older newly diagnosed with HIV at a 
publicly-funded testing site in a 52-county study area in central NC. Persons diagnosed at 
publicly-funded clinics represent 40% of all new HIV diagnoses in the study area. Persons whose 
reported address at the time of diagnosis was outside of the 52-county study area or was a 
correctional facility were excluded from analysis.  
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Exposure Assessment:  
 Residential addresses of all new HIV cases were geocoded to an ESRI-supplied NC street 
basemap using ArcGIS (version 10.1, ESRI, Redlands, CA). Persons with an address that could 
not be geocoded or who did not provide a full address were geocoded to a population-weighted, 
random point in the provided zip code. Census tract at diagnosis was assigned based on the 
geocoded residential address.  
 We identified a total of 326 publicly-funded HIV testing sites in NC providing samples to 
the state lab of public health for processing [Figure 7.1].
16
 The physical addresses of these sites 
were geocoded using the same method described above. The street network distance (miles) 
between each case’s residential address and both 1) the testing site of diagnosis and 2) the closest 
publicly-funded testing site were calculated in ArcGIS using the Network Analyst extension.  
 The most appropriate form for the continuous distance variables for modeling of the 
association between distance and the risk for late-stage diagnosis was assessed. Because the 
dose-response relationship did not appear to be linear and an empirically derived cut-point was 
evident (data not shown), we dichotomized both distance variables (≤ 5 miles versus >5 miles).  
Outcome Assessment:  
Using a 3-step process based on testing results reported in eHARS for all new diagnoses, 
we assigned a stage of disease at diagnosis: acute HIV infection (AHI), recent HIV infection 
(RHI), chronic HIV infection (CHI), and AIDS. The NC Screening and Tracing of Active 
Transmission (STAT) program has identified persons diagnosed with AHI (antibody-negative 
test result with reproducibly positive HIV RNA) since 2002. All STAT cases were linked to 
eHARS to indicate the AHI diagnosis in eHARS. Next, all cases diagnosed with AIDS in 
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eHARS (as defined by either 1) CD4 cell count <200 cells/mm
3
, 2) CD4 count < 14 percent of 
all lymphocytes, or 3) a diagnosis of one or more AIDS-defining illnesses) at the time of or 
within 6 months of an HIV diagnosis were identified. For the remaining cases, the CDC-
administered serologic testing algorithm for recent HIV seroconversion (STARHS) results were 
used to approximate RHI (≤6 months) from CHI (>6 months), based on a normalized optical 
density cut-point of <0.8 on the BED assay.
17
 All non-AHI and non-AIDS cases without 
STARHS testing results were excluded from analysis.  
In all subsequent analyses, we considered AHI and RHI diagnoses as “early stage” 
disease and CHI and AIDS diagnoses as “post-early stage” disease. 
Statistical Analysis: 
Because place frames a person’s behavior, we assessed the presence of spatial 
autocorrelation between the geocoded addresses of early and late diagnoses with the global 
Moran’s I statistic in ArcGIS. This test statistic evaluates whether diagnoses are clustered, 
dispersed or random in space by stage of disease.
152
 The Global Moran’s I test statistic was 
statistically non-significant (p=0.5), suggesting the observed spatial pattern of post-early-stage 
disease diagnoses is likely random and spatial autocorrelation is not present in these data. 
Therefore, we proceeded without accounting for spatial autocorrelation. 
Log-binomial regression models using generalized estimating equations with a compound 
symmetry correlation matrix were fit to estimate prevalence ratios (PR) and robust 95% 
confidence intervals (CI) for post-early-stage diagnoses by distance (closest site and site of 
diagnosis). Census tracts, which served as a proxy for unobserved characteristics (e.g. education, 
income, and employment), were used to account for the clustering of the outcome at the 
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neighborhood level. Models were adjusted for race/ethnicity and period of diagnosis based on a 
review of the literature and construction of a directed acyclic graph. 
All statistical analyses were conducted in SAS version 9.3 (Cary, NC).  
Results: 
Among 4023 persons diagnosed with HIV at publicly-funded testing sites in the 52-
county study area between 2005 and 2013, 3242 (80.6%) had enough information in eHARS to 
classify stage of disease at diagnosis. Of these, 26 cases were excluded because their address 
could not be geocoded. Distance parameters in ArcGIS could not be calculated for an additional 
188 cases, resulting in a study population of 3028 persons (1018 early-stage and 2010 post-early-
stage diagnoses). Most new diagnoses were black (N=2144; 70.8%), men who have sex with 
men (MSM) (N=1622; 53.6%), and residing in an urban area (N=2812; 92.9%). The median age 
was 29 years (IQR 23-40) [Table 7.1].  
Overall, 1145 (37.8%) of cases were diagnosed at a publicly-funded testing site that was 
≤5 miles from their place of residence. Of the remaining 1883 cases who were diagnosed at 
publicly-funded testing site >5 miles from their place of residence, 1273 (67.6%) lived within 5 
miles of a different publicly-funded testing site. 
Compared to post-early-stage diagnoses, a larger proportion of early-stage diagnoses 
were black (74.5% versus 69.0%) and MSM (61.4% versus 49.6%). Early-stage diagnoses were 
also more common in the later time period (2011-2013) (28.3% versus 23.1%). Persons 
diagnosed during early stages had a lower median age (25 versus 32 years) [Table 7.1]. 
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Some newly-diagnosed persons traveled longer distances than geographically necessary 
to test. All cases lived within 30 miles of a publicly-funded testing facility, with three-quarters 
living within 5 miles of a facility. The median distance traveled to the site of diagnosis was 
greater than median distance to the closest site [6.6 miles (IQR 3.6-12.3) versus 2.1 miles (IQR 
1.1-4.1)]. Compared to other groups, the prevalence of persons diagnosed with post-early-stage 
disease at testing sites >5 miles from their place of residence but living within 5 miles of a 
different publicly-funded testing site was slightly elevated (69.8%) [Table 7.2].  
In unadjusted analyses, the prevalence of post-early stage diagnosis was slightly greater 
among persons living >5 miles from their site of diagnosis (PR=1.08, 95% CI 1.02-1.14), while 
living >5 miles from the closest testing site had no association with no-early stage diagnosis 
(PR=0.97, 95% CI 0.91-1.03). There was no impact of adjustment for race/ethnicity and period 
of diagnosis on either of these associations [Table 7.3].  
The slightly increased prevalence of post-early-stage diagnoses among cases who were 
diagnosed at a site that was >5 miles from their residence occurred primarily among persons who 
lived within 5 miles of a different publicly-funded testing site in both unadjusted (PR=1.10, 95% 
CI 1.05-1.17) and adjusted analyses (PR=1.09, 95% CI 1.03-1.16) [Table 7.3]. This translated to 
an approximately 6% increase in the absolute prevalence of post-early-stage disease in this group 
compared to those who tested at a site within 5 miles of their residence [unadjusted 
difference=6.5% (2.7-10.2%); adjusted difference=6.2% (2.4-9.9%)]. The prevalence of post-
early stage diagnoses was not increased among persons that lived >5 miles of any testing site. 
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Discussion: 
 Distance to publicly-funded HIV testing facilities plays a role in test-seeking behaviors in 
central NC. An increase in prevalence of post-early-stage diagnoses was observed among 
persons diagnosed farther away from their place of residence. Most of the elevated prevalence 
occurred in persons who were diagnosed at testing facilities that were >5 miles from their 
residence yet lived within 5 miles of a different testing facility, suggesting factors other than 
distance may contribute to delays in testing.  
A substantial proportion of HIV testing in the southeastern United States is conducted in 
health departments.
34
 We identified 326 publicly-funded testing sites servicing the 100 NC 
counties. In our analysis, all identified HIV-infected persons lived within 30 miles of a testing 
facility and over 75% lived within 5 miles, indicating that free or low-cost HIV testing services 
are widely available.  
The location of HIV testing appears to depend on factors beyond distance alone. 
Perceptions about disease-related stigma, inadequate HIV services, and lack of confidentiality 
may influence people living in the rural south to seek HIV testing (and possibly care) from 
facilities that are geographically farther away.
27,79,86,183,186
 Furthermore, where a person chooses 
to access medical services is often a function of accumulation, whereby testing and care choices 
are made relative to the location of other persons (e.g. friends, family) or activities (e.g. 
employment, school) rather than their place of residence.
187
 In this analysis, we estimated the 
proportion of persons for whom factors other than distance influence their choice to travel farther 
than geographically necessary to test for HIV. While the relative increase in observed prevalence 
of post-early-stage diagnosis in this group was relatively small, it is not inconsequential. The 
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approximately 120 post-early-stage diagnoses travelling farther than geographically necessary to 
test did not benefit from early care and treatment. Interventions addressing non-geographic 
factors related to accessibility of HIV services may be valuable to promote early identification of 
HIV in this setting.  
While street network distance between two points is an easy-to-derive measure from data 
collected for surveillance purposes, it may not fully explain all dimensions of geographic 
accessibility to HIV services.
187
 Communities differ with regard to the type and efficiency of 
available transportation systems.
188
 This could impact both the cost and travel time required to 
get from one location to another that may not be evident when considering distance alone.  
Surveillance data provides a real-world depiction of the test-seeking behaviors of HIV-
infected persons that has been unmodified by study monitoring. CD4 cell counts are traditionally 
used to classify the disease stage of HIV-infected persons.
181
 However, the novel algorithm 
presented in this analysis takes advantages of standard HIV testing results reported in NC 
surveillance databases to estimate disease stage at diagnosis. While misclassification of AIDS 
cases as recent infection by STARHS testing results is possible,
112
 we tried to minimize this 
phenomenon by classifying and removing AIDS cases prior to our assessment of STARHS 
results.  
Delays in HIV testing were apparent among persons who could in theory have tested at a 
nearby publicly-funded facility, but chose to travel longer distances to test. The reasons for 
travelling farther to test for HIV and delaying diagnosis are likely varied and may spill over to 
delays in linking to HIV care and initiating treatment.
34
 Additional HIV testing sites may not be 
the most effective use of limited resources. Rather, interventions increasing the accessibility of 
 105 
 
HIV services (e.g. providing transportation and lowering perceived stigma) for people travelling 
longer distances to receive a diagnosis could help in disease awareness, management, and active 
care engagement.   
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Tables and Figures 
Figure 7.1 Location of All Publicly-funded HIV Testing Sites in North Carolina  
 
CAPTION: All publicly-funded testing sites in NC were geocoded to an ESRI (Redlands, California)-
supplied NC street basemap using ArcGIS (version 10.1, ESRI). The green circles represent 
testing sites where at least 1 case included in this analysis was diagnosed. The pink squares 
represent all other publicly-funded testing sites in the state. The heavy black line indicates the 
study area used to identify cases.   
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Table 7.1: HIV Diagnosis Demographics of persons newly-diagnosed with HIV in a 52 county region in 
Central North Carolina, 2005-2013 
  
Total Cases 
N=3028 
Early Stage Cases 
N=1018 
Post-Early Stage 
Cases 
N=2010 
  Median IQR Median IQR Median IQR 
Age 29 (23-40) 25 (21-35) 32 (24-42) 
 N % N % N % 
Stage of Diagnosis         
AHI 156 (4.9) 156 (4.9) -- -- 
RHI 904 (28.1) 904 (28.1) -- -- 
CHI 1659 (51.6) -- -- 1659 (51.6) 
AIDS 497 (15.5) -- -- 497 (15.5) 
Gender         
Female 717 (23.7) 238 (23.4) 479 (23.8) 
Male 2311 (76.3) 780 (76.6) 1531 (76.2) 
Race         
Black 2144 (70.8) 758 (74.5) 1386 (69.0) 
White NH 472 (15.6) 161 (15.8) 311 (15.5) 
Hispanic 302 (10.0) 65 (6.4) 237 (11.8) 
Other 110 (3.6) 34 (3.3) 76 (3.8) 
Risk Group         
MSM 1622 (53.6) 625 (61.4) 997 (49.6) 
IDU 69 (2.3) 24 (2.4) 45 (2.2) 
MSM/IDU 17 (0.6) 6 (0.6) 11 (0.5) 
Other 444 (14.7) 125 (12.3) 319 (15.9) 
Region         
2: Charlotte 978 (32.3) 306 (30.1) 672 (33.4) 
3: Winston-Salem 589 (19.5) 224 (22.0) 365 (18.2) 
4: Raleigh 980 (32.4) 325 (31.9) 655 (32.6) 
5: Fayetteville 481 (15.9) 163 (16.0) 318 (15.8) 
Period of Diagnosis         
2005-2007 970 (32.0) 308 (30.3) 662 (32.9) 
2008-2010 1305 (43.1) 422 (41.5) 883 (43.9) 
2011-2013 753 (24.9) 288 (28.3) 465 (23.1) 
Testing Site         
HIV Counselling 
and Testing Agency 
2265 (74.8) 771 (75.7) 1494 (74.3) 
STD Clinic 212 (7.0) 79 (7.8) 133 (6.6) 
Outpatient Facility 294 (9.7) 94 (9.2) 200 (10.0) 
Other 257 (8.5) 74 (7.3) 183 (9.1) 
Rural/Urban         
Urban 2812 (92.9) 949 (93.2) 1863 (92.7) 
Rural 216 (7.1) 69 (6.8) 147 (7.3) 
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Table 7.2: Distance Measures of persons newly-diagnosed with HIV in a 52 county region in Central 
North Carolina, 2005-2013 
  
Early Stage Cases 
N=1018 
Post-Early Stage 
Cases 
N=2010 
 
  Median IQR Median IQR  
Distance to Testing Site  
  of Diagnosis (Miles) 6.5 (3.4-12.7) 6.7 (3.7-12.1) 
 
Distance to Closest    
  Testing Site (Miles) 2.1 (1.1-4.2) 2.2 (1.1-4.1) 
 
 N % N % 
Prevalence of  
Post-Early Stage 
Diagnoses* 
Distance to Testing Site  
  of Diagnosis 
     
≤5 miles 419 (41.2) 726 (36.1) 63.4 
>5 miles 
599 (58.8) 1284 (63.9) 68.2 
Distance to Closest  
  Testing Site 
    
 
≤5 miles 803 (78.9) 1615 (80.3) 66.8 
>5 miles 215 (21.1) 395 (19.7) 
64.8 
Distance to Testing Site  
  of Diagnosis 
      
 
≤5 miles 419 (41.2) 726 (36.1) 63.4 
>5 miles, but closest  
  testing site within  
  5 miles 
384 (37.7) 889 (44.2) 69.8 
>5 miles and closest  
  testing site >5  
  miles 
215 (21.1) 395 (19.7) 64.8 
Tested at Closest Testing  
  Site 
        
 
Yes 148 (14.5) 295 (14.7) 66.3 
No 870 (85.5) 1715 (85.3) 66.6 
*per 100 people 
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Table 7.3: Prevalence Ratio (PR) and 95% Confidence Intervals (CI) Estimates of Post-Early Stage  
Diagnoses in a 52 county region in Central North Carolina, 2005-2013 
  
Crude Adjusted* 
 
N PR 95% CI PR 95% CI 
Distance to Testing Site of Diagnosis  
        
≤5 miles 1145 1.00 
 
1.00 
 
>5 miles 1883 1.08 (1.02-1.14) 1.07 (1.02-1.13) 
Race  
  
   
Black 2144 0.98 (0.92-1.05) 0.99 (0.93-1.06) 
White 472 1.00 
 
1.00 
 
Hispanic 302 1.19 (1.09-1.30) 1.20 (1.10-1.31) 
Other 110 1.07 (0.93-1.23) 1.08 (0.94-1.24) 
Period  
  
   
2005-2007 970 1.10 (1.03-1.18) 1.11 (1.04-1.19) 
2008-2010 1305 1.10 (1.02-1.17) 1.11 (1.04-1.19) 
2011-2013 753 1.00  
1.00 
 
Distance to Closest Testing Site  
        
≤5 miles 2418 1.00 
 
1.00 
 
>5 miles 610 0.97 (0.91-1.03) 0.98 (0.92-1.04) 
Race  
  
   
Black    0.98 (0.91-1.05) 
White    1.00 
 
Hispanic    1.19 (1.09-1.30) 
Other    1.07 (0.94-1.23) 
Period      
2005-2007    1.11 (1.04-1.19) 
2008-2010    1.11 (1.03-1.18) 
2011-2013    1.00   
Distance to Testing Site of Diagnosis  
        
≤5 miles 1145 1.00 
 
1.00 
 
>5 miles but closest TS ≤5 miles 1273 1.10 (1.05-1.17) 1.09 (1.03-1.16) 
>5 miles and closest TS >5 miles 610 1.02 (0.95-1.10) 1.02 (0.95-1.10) 
Race  
  
   
Black    0.98 (0.92-1.05) 
White    1.00 
 
Hispanic    1.18 (1.09-1.29) 
Other    1.08 (0.94-1.23) 
Period      
2005-2007    1.11 (1.04-1.19) 
2008-2010    1.11 (1.04-1.19) 
2011-2013    1.00   
*Each model adjusted for Race and Testing Period  
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CHAPTER EIGHT: DISCUSSION 
Diagnosis, presentation to care, and initiation of antiretroviral therapy (ART) during the 
early stages of HIV have substantial individual and public health benefits.
1-6
 However, current 
estimates of the HIV care continuum, or care cascade, indicate that most HIV-infected persons in 
the US are not achieving viral suppression.
8,154
 The purpose of this dissertation was to 1) 
characterize the cascade-related behaviors of persons participating in active transmission 
networks and 2) examine the geographic barriers to early diagnosis. Improved understanding of 
when a person is diagnosed and the subsequent cascade-related behaviors of HIV-infected 
persons are necessary to develop innovative interventions against HIV.  
Specifically, this dissertation addressed three aims: estimation of the relative 
contributions of persons with AHI, previously undiagnosed established infection, and diagnosed 
established infection to ongoing transmission in NC (Aim 1), examination of how the spatial 
clustering of HIV diagnoses by stage of disease has changed as a result of the CDC’s 
recommendations for routine, opt-out testing  (Aim 2) and assessment of the effect of distance to 
testing sites on stage of disease at diagnosis (Aim 3). 
Aim 1: HIV transmission in NC 
Summary of Findings 
In Aim 1, we assessed HIV status awareness and the diagnosis, care, treatment, and viral 
suppression status for 1) all traceable partners and 2) the most likely transmission source for 
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persons diagnosed with acute HIV infection (index AHI cases) in NC between 2002 and 2013 
using surveillance data collected as part of the STAT program and data collected via the 
CHAVI-001 study. Based on prior modeling studies that used a combination of empirical data 
and assumptions (when empirical data was unavailable),
10,11
 we hypothesized that the majority of 
these transmission events would be due to partners who were previously unaware of their disease 
status. However, the results of this analysis did not support this hypothesis.  
A total of 358 index AHI cases named 932 partners, of which 218 were HIV-infected 
(162 (74.3%) previously-diagnosed, 11 (5.0%) new AHI, 45 (20.6%) new CHI).  Among the 162 
previously-diagnosed partners, 16.0% were not in care, 31.5% were in care but not on ART, and 
29.6% were in care and on ART at the time of the index AHI case diagnosis. Among the 40 
previously-diagnosed partners in care and with an available VL, 75.0% were unsuppressed at the 
time of their most recent VL prior to the index AHI case’s diagnosis date. Approximately half 
(48.6%) of index AHI cases named at least 1 HIV-infected partner. The remaining index AHI 
cases only named potential transmitting partners of unknown status, did not name any partners 
during the 8 weeks prior to their diagnosis, or only named HIV-uninfected partners. 
Most transmission events appeared attributable to previously-diagnosed partners (76.9%, 
5
th
 and 95
th
 percentile 75.3-78.2%). Among previously-diagnosed partners, only 27.1% (5
th
 and 
95
th
 percentiles 25.9-28.8%) were reported to be in care and on treatment near the index AHI 
case diagnosis date. In the subset study of 33 phylogenetically-linked cases and partners, most 
partners had been previously-diagnosed (60.6%, 95% CI 43.9-77.3%), although the contribution 
is smaller than observed in surveillance data collected as part of the STAT program. 
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Interpretation 
Our findings highlight the fact that previously-diagnosed persons continue to engage in 
high-risk behaviors with persons who up until recently, were HIV-uninfected. A substantial 
proportion of observed transmission events appear attributable to contact with previously-
diagnosed partners in North Carolina, where HIV disproportionately affects African Americans 
living in both urban and rural areas. Moreover, previously-diagnosed partners were uncommonly 
reported to be in care, on treatment and virally suppressed at the time of contact with the index 
AHI case, increasing the likelihood of transmission.
158,159
  
Public Health Significance 
This analysis provides the first empirically collected estimates of the diagnosis, care, 
treatment, and viral suppression status of persons involved in networks where HIV is actively 
being transmitted. This information is important for designing, modeling, and targeting HIV care 
and treatment services from both a clinical and prevention perspective.  
Estimates produced as a part of this dissertation can be used on both the individual and 
public health level to communicate the level of risk of onward transmission among persons not 
in care or on effective treatment. Most observed transmission in NC appeared to be due to 
contact with previously-diagnosed partners, reinforcing the need for improved linkage and 
retention in care after diagnosis.  
Additionally, these estimates can be used to update mathematical models estimating the 
likelihood of transmission. The contribution of newly-infected persons to onward transmission in 
previous mathematical models was 10-50% higher than observed in any population under 
analysis in this dissertation.
10,11
 Because mathematical models can inform policy decisions and 
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resource allocation, accurate estimates of cascade-related behaviors of potential transmitting 
partners are necessary to maximize the public health benefits of these decisions.  
Limitations 
Prior modeling studies and our current empirical work approach the research question in 
different populations and from different angles, each with its own biases related to difficult-to-
verify assumptions and missing information. In this study, approximately half of the index AHI 
cohort named at least one status-unknown or anonymous partner, and over one-third named only 
unknown/anonymous partners. Undoubtedly, some unknown/anonymous partners transmitted 
HIV, but could not be included in our analysis of cascade stages. Status-unknown partners have 
no record of a positive test in surveillance databases under the name provided by the index AHI 
case and either refused HIV testing or could not be located. HIV infection may be more 
prevalent among persons refusing HIV testing. If HIV-infected, status-unknown partners have 
not yet been diagnosed, were misnamed or were diagnosed outside the jurisdiction area. 
Anonymous partners did not have any identifiable information, and consequently, may be more 
likely to engage in riskier behaviors and less likely to test for HIV or enter care than identifiable 
partners.  
Despite proximity to the date of infection, uncertainty exists in the identification of the 
transmitting partner. Approximately 20% of index AHI cases did not name any potential 
transmitting partners. Furthermore, most of the partnerships under analysis were not confirmed 
as known transmission pairs through phylogenetic linkages. The source of transmission cannot 
be verified in partnerships where phylogenetic testing was not done, even if the status of all 
partners was known and only one was HIV-infected. Even for pairs that have been 
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phylogenetically linked, a shared intermediary transmitting partner provides another possible 
explanation for the linkage.  
Finally, partner viral suppression status at the time of transmission is difficult to assign 
based on information reported for surveillance purposes. Only half of the previously-diagnosed 
partners had an available VL in surveillance databases near the time of the index AHI case 
diagnosis and approximately 20% of these partners were virally suppressed. If partners are truly 
virally suppressed, HIV transmission is known to be unlikely.  
Future Research Directions 
 To improve the understanding of the contribution previously-diagnosed partners make to 
onward HIV transmission, additional estimates of risk behaviors are required. Published 
mathematical models of transmission risk make assumptions about difficult-to-verify risk 
behaviors at the time of transmission, specifically the frequency of unprotected anal sex acts.
10,11
 
We are currently quantifying the risk behaviors reported by index AHI cases as part of the STAT 
program, including type of partnership (sexual or needle-sharing), sexual positioning, frequency 
of sex acts, and condom use. While we are unable to phylogenetically-confirm linkage in each 
potential transmitting partnership, the repeated sampling methods used in this aim can provide 
reasonable estimates of risk behaviors that increase the likelihood of HIV transmission. 
Aim 2: Spatial assessment of early and late stage HIV diagnoses in NC  
Summary of Findings 
In this analysis, we examined the geographic patterns and clustering of early and late 
stage diagnoses in a 52-county study area in central NC both before and after the adoption of the 
CDC’s recommendations for routine, opt-out testing. We hypothesized that persons diagnosed 
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with early HIV infection would be more likely to cluster in urban centers both before and after 
the CDC’s recommendations, while late stage diagnoses would be more geographically 
dispersed.  
Minimal overlap of high rate diagnoses (top 10 percentile) by disease stage and testing 
period was observed in the 52-county study area in NC between 2005 and 2013. However, at 
non-high rates (top 25
th
 and 50
th
 percentile), a disproportionate level of overlap was observed, 
suggestive of an underlying, “core” HIV diagnosis area in NC.  
The overlap of EHI and CHI diagnoses at the highest rates (top 10 percentile) was 
relatively constant in terms of both quantity and location across all periods. High rate EHI and 
CHI diagnoses occurred predominantly in the urban centers, with a few small pockets scattered 
across the study area. Between Period 1 (2005-2007) and Period 2 (2008-2010), an increase in 
the number of overlapping high rate (top 10 percentile) areas was observed between CHI and 
AIDS diagnoses, possibly indicating cases that would have been diagnosed during AIDS were 
being found earlier and diagnosed during CHI in these areas. Most of the increase in overlap was 
observed in the southeastern part of the study area.  
 Overlap at the highest rates (top 10 percentile) of disease stage across each testing period 
was relatively low. Overlap of high rate EHI diagnoses across time was spatially dynamic, 
indicating EHI was consistently diagnosed across the study area and the location of high rate 
EHI diagnoses changed over time. Compared to EHI and CHI diagnoses, overlap of high rate 
AIDS diagnoses was highest across all 3 testing periods and was geographically prominent in the 
southeastern part of the study area.  
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Interpretation 
An underlying, “core” area for HIV diagnosis was observed across each testing period 
and disease stage, but only at lower diagnosis rates. In these areas, stage of disease does not 
appear to be heavily influenced by location or the adoption of the CDC’s testing 
recommendations. Areas with high rates of HIV diagnosis by disease stage and testing period 
were more spatially dynamic, with minimal observed overlap.  
Spatial trends in EHI diagnosis could indicate changing trends in the underlying epidemic 
in central NC. Alternatively, changes could be due to shifts in testing activity, possibly due to the 
adoption of routine, opt-out testing. Overlap of high rate EHI diagnoses was rare, particularly 
outside of urban centers. Interventions other than routine, opt-out testing may be necessary to 
consistently identify early infection. Areas of persistent AIDS diagnoses suggest the routine, opt-
out testing policies fail to find every HIV-infected person early. In this analysis, substantial 
overlap of high rate AIDS diagnoses across time periods was observed in the southeastern part of 
the state. Promoting HIV testing and possibly targeting testing to at-risk persons in this region 
could reduce the rates at which AID is diagnosed in this region. 
Public Health Significance 
 Improved understanding of the geographic patterns and clustering of HIV diagnoses 
across North Carolina is important for informing policymakers of current trends and facilitating 
effective targeting of limited HIV prevention resources. One of the goals of the CDC’s 
recommendations was to identify HIV-infected persons earlier during the course of their 
infection to achieve the benefits of care and ART sooner.
14
 Our analysis suggests that targeted 
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efforts to identify EHI in areas with high rates of CHI may be an effective strategy to diagnose 
and link HIV-infected persons to care earlier during their infection.  
 A persistence of AIDS cases across all testing periods in the southeast portion of the 
study area suggests HIV-infected persons in this part of the state are not requesting or not being 
offered HIV testing early in their infection. The reasons for late stage testing are likely varied 
and include noncompliance with the CDC’s recommendations on the part of providers as well as 
the patient’s perceptions of risk, inaccessibility of HIV services, and stigma.34 Targeted 
interventions emphasizing the importance of early diagnosis may be necessary in these parts of 
the state with persistent or re-emerging high rates of AIDS diagnoses. 
Limitations 
We present a novel method to classify stage of disease based on testing results. This 
algorithm is not without bias. The BED assay used for STARHS testing is a nonspecific test, 
whereby a proportion of persons with severe immunosuppression or with long-standing infection 
and on antiretroviral therapy can be misclassified as RHI.
112,113
 However, we assumed this 
misclassification was minor since our study population included only newly-diagnosed persons 
who were not likely to have a history of ART use prior to STARHS testing. Furthermore, we 
removed all persons diagnosed with AIDS prior to the assignment of recent infection, lowering 
the likelihood of any potential misclassification. It is possible that the observed overlap of high 
rate EHI and AIDS diagnoses represents some expected misclassification. 
The UMBME method used in this analysis to map diagnosis rates effectively imputes 
disease rates to areas where data are missing. This smoothing process can result in the addition 
of “noise” in the estimated rates.144 Therefore some of the high rate areas may be an artifact of 
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the smoothing process used in UMBME estimation. To address this, we aggregated cases to the 
census tract level and to three-year testing periods. Aggregation ensures data are spatially 
correlated, improving the smoothing of UMBME models.
144
 However, these larger units of 
aggregations do mask some sub-unit variation and could result in misinterpretation of true 
underlying spatiotemporal patterns.
182
 
As part of this analysis, we excluded over half of the newly-diagnosed HIV infections to 
assess overall positivity rates for people diagnosed at publicly-funded testing clinics. We also 
excluded an additional 20% of cases whose address could not be geocoded. Therefore, the rates 
presented in this analysis likely underestimate the total diagnosis rates in each census tract. 
Furthermore, we did not have an accurate count of the testing population at publicly-funded 
testing sites. We deduplicated the testing events in the CTR system using a software program 
with over 90% sensitivity and positive predictive value when a reviewer’s decision is used as the 
gold standard.
141
 However, it is likely that this program failed to link tests that were true matches 
and linked tests that should have been matched. This misclassification is likely nondifferential.  
Future Research Directions 
 In this analysis, we were able to estimate the diagnosis rates in time and space originating 
from publicly-funded testing sites. An obvious extension of this work would be to apply this 
same analysis to all persons diagnosed at both public and private testing sites. Estimation of the 
underlying testing population may be difficult to determine in such an analysis. However, 
density (e.g. number of cases per tract divided by the area of the tract) is a valid measure for 
estimating rates in other similar analyses
145
 and could be used when the underlying testing 
population is difficult to estimate. 
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 We restricted this analysis to a 52-county study area in central North Carolina where 
approximately 80% of all HIV diagnoses occur so that our rates would not be as influenced by 
the “noise” resulting from the mountain and coastal regions of the state where HIV diagnosis 
rates are lower. However, our study area was comprised of urban and rural areas with both high 
and low rates. Estimation of the true “latent” rate in these rural areas with low rates may have 
been overly influenced by high rate urban areas in the study area.
144
 Choice of the study 
boundary therefore has the potential to affect the results and their interpretation for public health 
decision making purposes. Conducting this analysis within each region or county, where rates 
are likely to be similar, provides a better estimation of HIV diagnosis patterns on a local level 
which can translate to more effective use of resources.  
Aim 3: Distance to a testing site and stage of disease at diagnosis  
Summary of Findings 
 The purpose of the analysis in Aim 3 was to estimate the effect of distance to a publicly-
funded testing site on post-early stage diagnosis in central North Carolina. The results of this 
analysis supported my hypothesis that persons living farther from the test site where they were 
diagnosed were more likely to be diagnosed with later during the course of their disease.  
In unadjusted and adjusted models, the prevalence of post-early-stage diagnosis was 
greater among persons living >5 miles from the testing site of diagnosis (PR adjusted for 
race/ethnicity and time period =1.07 95% CI 1.02-1.13). However, living >5 miles from the 
closest testing site did not result in an increase in the prevalence of post-early-stage diagnosis 
(PR adjusted for race/ethnicity and time period=0.98 95% CI 0.92-1.04). Most of the increased 
prevalence of post-early-stage diagnoses occurred among cases who were diagnosed at a testing 
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diagnosed at a testing site that was >5 miles from their residence, but lived within 5 miles of a 
different publicly-funded testing site (PR adjusted for race/ethnicity and time period=1.09 95% 
CI 1.03-1.16). 
Interpretation 
Despite the fact that publicly-funded HIV testing sites are widely available across North 
Carolina, some people choose to travel farther distances than geographically necessary to test. 
These people may be more likely to enter care later during the course of their disease, limiting 
the potential effectiveness of HIV care and treatment. Proximity to the closest testing site did not 
appear to influence when HIV-infected persons tests, suggesting distance alone is not a major 
impediment to HIV testing behaviors. Perceptions about disease-related stigma, inadequate HIV 
services, and lack of confidentiality may influence people living in the rural south to seek HIV 
testing from facilities that are geographically farther away.
27,79,86,183
  
Public Health Significance 
 To fully benefit from the ART, HIV-infected persons should not only be aware of their 
disease status, but also be diagnosed early. Nationwide, a substantial proportion of HIV-infected 
persons do not present for HIV testing until late in their course of their infection
8
; approximately 
half of all AIDS diagnoses in NC in 2010 were made at the same time or within six months of 
their HIV diagnosis.
16
 Persons presenting at an advanced stage of immunosuppression are at high 
risk of adverse clinical events and death.
64
 However, the reasons for delays in testing are varied 
and complex.
5,12,31,53-61,189
  
In this analysis, we observed a small, yet meaningful increase in post-early stage 
diagnoses among persons who travelled longer distances to receive an HIV test than 
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geographically necessary. For these people, accessibility to HIV testing was not measured by 
distance alone. Other factors, possibly including perceptions about the quality of the HIV 
services and stigma could lead to increases in the distances traveled for a test and consequently 
delays in testing. Additional HIV care and testing sites may not be the most effective use of 
limited public health resources. Rather, interventions increasing the non-distance factors related 
to accessibility of HIV services (e.g. providing transportation and lowering perceived stigma) for 
people travelling longer distances to receive a diagnosis could help in the management of their 
disease status while keeping them actively engaged in care.  
Limitations 
 While street network distance between two points is an easy-to-derive measure from data 
collected for surveillance purposes, it may not fully explain all dimensions of geographic 
accessibility to HIV services.
187
 Communities differ with regard to the type and efficiency of 
available transportation systems.
188
 This could impact both the cost and travel time required to 
get from one location to another that may not be evident when considering distance alone. 
Furthermore, perceptions related to stigma and the quality of HIV-related services were not 
measured. However, the use of GEE in this analysis accounts for some of these unmeasured, 
neighborhood-wide perceptions during statistical modeling.  
The definition used in this analysis for early stage disease was heavily dependent on BED 
assay results used as part of STARHS testing. Because the BED assay is a nonspecific test for 
RHI, some persons with AIDS were likely misclassified as having RHI. We tried to minimize 
this phenomenon by classifying and removing AIDS cases prior to our assessment of BED assay 
results, however some misclassification is likely to have occurred. 
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Future Research Directions 
Diagnoses made later during the course of the disease are generally more common among 
persons who are not perceived, or who do not perceive themselves to be at high risk for 
infection, persons not actively offered HIV testing, and marginalized groups.
44
 These factors are 
likely intertwined with structural barriers, such as the distance a person travels to receive a 
diagnosis for HIV. In this analysis, we identified that persons travelling longer distances than 
geographically necessary are more likely to test later during the course of their disease. Focus 
groups among persons requesting HIV tests from a publicly-funded testing site may provide 
insight into the role stigma, perceived risk, quality of HIV services, and structural barriers 
(including distance) played in the selection a testing site.  
The results from the focus groups can also be used to formulate more accurate measures 
of “accessibility” beyond the network distance measure used in this analysis. Improving the 
measurement of accessibility translates to increased accuracy in its estimated effect on late stage 
diagnosis. This can in turn lead to a more effective allocation of public health resources towards 
interventions with the highest likelihood of success.   
Final Remarks 
HIV is spatially dispersed across central North Carolina; however diagnosis rates are 
highest in urban centers. The location of high rates of early infection has changed over time 
indicating possible shifts in the testing activity and/or the epidemic itself. The southeastern 
corner of the state displayed persistently high rates of AIDS diagnoses. Interventions focused on 
early detection of disease in these areas could impact morbidity, mortality, and transmission in 
this part of the state. Reasons for late stage diagnoses are likely varied. Here, we identified that 
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persons travelling longer distances than geographically necessary are more likely to be diagnosed 
with post-early stage HIV infection. Perceptions of risk, stigma, and accessibility of HIV 
services provide possible explanations for travelling farther than necessary for an HIV test.  
Once diagnosed, it is imperative to engage HIV-infected persons in care because 
previously-diagnosed persons continue to engage in risk behaviors with persons who up until 
recently, were uninfected. Most transmission in NC appears to be a result of contact with people 
who are aware of their infection. Ensuring viral suppression through care and treatment of these 
previously-diagnosed persons could effectively prevent transmission and lower HIV incidence in 
this setting.
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APPENDIX 1: HIV COUNSELING AND TESTING REPORT FORM 
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APPENDIX 2: STAT DATA COLLECTION FORMS 
 
  
1
2
7
 
 128 
     
 
  
1
2
9
 
APPENDIX 3: AIM 1 SUPPLEMENTAL TABLES AND FIGURES 
 Table A3.1 Diagnosis, care, and treatment status estimates for HIV-infected partners 
 
Transmission 
Landscape 
Most Likely Transmission Source: 
Unconfirmed Linkage 
Most Likely 
Transmission Source: 
Confirmed Linkage 
STAT: 
All Identified HIV-
infected Partners 
 
STAT Type A: 
1 potential transmitting 
partner with all other 
partners testing HIV-
negative 
 
STAT Type B: 
>1 potential 
transmitting partner 
with at least 1 
confirmed HIV-infected 
partner 
STAT Types A+B: 
≥1 potential 
transmitting partner 
with at least 1 
confirmed HIV-infected 
partner 
CHAVI-001: 
Phylogenetically-Linked 
Partner 
 
 HIV+ Partner N=218 
Index AHI N=106                                                     
HIV+ Partner N=106 
Index AHI N=68                                                                                             
HIV+ Partner N=112 
Index AHI N=174
HIV+ Partner N=218 
Index AHI N=33                                                    
HIV+ Partner N=33 
N ?̂? 95% CI N ?̂? 95% CI N ?̂? 
5th & 95th 
percentiles 
N ?̂? 
5th & 95th 
percentiles 
N ?̂? 95% CI 
New AHI 
 
11 0.050 
0.021-
0.080 
1 0.001 
0.000-
0.03 
10 0.076 
0.059-
0.103 
11 0.036 
0.029-
0.046 
3 0.091 
0.000-
0.189 
New CHI 
 
45 0.206 
0.153-
0.260 
23 0.217 
0.139-
0.295 
22 0.163 
0.118-
0.206 
45 0.196 
0.178-
0.213 
10 0.303 
0.146-
0.460 
Previously-
diagnosed,  not 
in care 
26 0.119 
0.076-
0.162 
19 0.179 
0.106-
0.252 
7 0.078 
0.059-
0.103 
26 0.140 
0.132-
0.149 
-- -- -- 
Previously-
diagnosed in 
care, not on ART 
51 0.234 
0.178-
0.290 
22 0.208 
0.130-
0.285 
29 0.278 
0.235-
0.309 
51 0.235 
0.218-
0.247 
-- -- -- 
Previously-
diagnosed, in 
care, on ART 
48 0.220 
0.165-
0.275 
19 0.179 
0.106-
0.252 
29 0.244 
0.206-
0.279 
48 0.204 
0.190-
0.218 
-- -- -- 
Previously-
diagnosed 
Unclassified 
Care & 
Treatment 
37 0.170 
0.120-
0.220 
22 0.208 
0.130-
0.285 
15 0.162 
0.132-
0.191 
37 0.190 
0.178-
0.201 
20 0.606 
0.439-
0.773 
NOTE: The diagnosis, care, and treatment status are presented for 1) all HIV-infected partners named by the index AHI cohort and identified by 
the STAT program, 2) the most likely transmission source among identified HIV-infected partners presented by the pattern of HIV-infected, 
  
1
3
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uninfected, and status-unknown partners reported to the STAT program and 3) phlyogenetically-linked partners identified via the CHAVI-001 
study. For estimates of the most likely transmission source where >1 potential transmitting partner was named, repeated random sampling was 
used to estimate diagnosis, care, and treatment status of the partner. NOTE: Potential transmitting partner refers to any partner reported in the 8 
week period prior to the index AHI diagnosis date who was not classified as HIV-uninfected (e.g. HIV-infected and status-unknown partners).  
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APPENDIX 4: AIM 2 SUPPLEMENTAL TABLES AND FIGURES 
Figure A4.1 Spatial and Temporal Covariance Plots from UMBME Estimation 
Disease 
Stage 
Spatial Temporal 
EHI 
A
 
B
 
CHI 
C
 
D
 
AIDS 
E
 
F
 
 
  
  
1
3
2
 
CAPTION: Spatial and temporal covariance plots estimated during UMBME modeling show the extent of spatial and temporal 
dependence of HIV diagnosis rates by stage of disease for the 52-county study area in central North Carolina from July 2005 to June 
2013. The spatiotemporal variance is defined by the y-intercept, or sill, and is highest for CHI diagnoses. The spatial and temporal 
dependence is defined by the distance along the x-axis where the covariance model becomes asymptotic.  
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Figure A4.2. Overlap of Disease Stage by Testing Period at the top 10, 25, and 50
th
 UMBME Diagnosis Rate Percentiles 
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CAPTION: Overlap of disease stage (early HIV infection [EHI], chronic HIV infection [CHI], AIDS) by percentile of diagnosis rate (top 10, 25, 
and 50
th
 percentile) during each testing period. The darkest color indicates overlap at all stages, the middle color indicates overlap of 2 stages, and 
the lightest color indicates no overlap. White indicates diagnoses indicate diagnosis rates at all three stages were lower than the diagnosis rate 
percentile presented.  
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Figure A4.3. Overlap of Testing Period by Disease Stage at the top 10, 25, and 50
th
 UMBME Diagnosis Rate Percentiles 
 Top 10 Percent Top 25 Percent Top 50 Percent 
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CAPTION: Overlap of testing period (2005-2007, 2008-2010, 2011-2013) by percentile of diagnosis rate (top 10, 25, and 50
th
 percentile) within 
each disease stage (early HIV infection [EHI], chronic HIV infection [CHI], AIDS). The darkest color indicates overlap at all testing periods, the 
middle color indicates overlap of 2 testing periods, and the lightest color indicates no overlap. White indicates diagnoses indicate diagnosis rates 
during all three testing periods were lower than the diagnosis rate percentile presented.  
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Figure A4.4. Top 10% Testing Rate Overlap by Study Period and Stage of Disease (UMBME Results) 
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CAPTION: Overlap of top 10 percentile of disease stage (early HIV infection [EHI], chronic HIV infection [CHI], AIDS) diagnosis rates 
estimated via UMBME during each testing period. Color indicates overlap. 
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Figure A4.5. Top 25% Testing Rate Overlap by Study Period and Stage of Disease (UMBME Results) 
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CAPTION: Overlap of top 25 percentile of disease stage (early HIV infection [EHI], chronic HIV infection [CHI], AIDS) diagnosis rates 
estimated via UMBME during each testing period. Color indicates overlap.  
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Figure A4.6. Top 50% Testing Rate Overlap by Study Period and Stage of Disease (UMBME Results) 
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CAPTION: Overlap of top 50 percentile of disease stage (early HIV infection [EHI], chronic HIV infection [CHI], AIDS) diagnosis rates 
estimated via UMBME during each testing period. Color indicates overlap.  
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Figure A4.7. Top 10% Testing Rate Overlap by Study Period and Stage of Disease (UMBME Results) 
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CAPTION: Overlap of top 10 percentile of testing period diagnosis rates estimated via UMBME across each diagnosis stage (early HIV infection 
[EHI], chronic HIV infection [CHI], AIDS). Color indicates overlap. 
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Figure A4.8. Top 25% Testing Rate Overlap by Study Period and Stage of Disease (UMBME Results) 
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CAPTION: Overlap of top 25 percentile of testing period diagnosis rates estimated via UMBME across each diagnosis stage (early HIV infection 
[EHI], chronic HIV infection [CHI], AIDS). Color indicates overlap. 
  
  
1
4
2
 
Figure A4.9. Top 50% Testing Rate Overlap by Study Period and Stage of Disease (UMBME Results) 
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CAPTION: Overlap of top 50 percentile of testing period diagnosis rates estimated via UMBME across each diagnosis stage (early HIV infection 
[EHI], chronic HIV infection [CHI], AIDS). Color indicates overlap. 
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Table A4.1. Statistically-significant high rate clusters identified by the Kulldorff’s Spatial Scan Statistic 
 EHI CHI AIDS 
 
Cluster 
Number 
of 
Census 
Tracts 
Relative 
Risk p-value Cluster 
Number 
of 
Census 
Tracts 
Relative 
Risk p-value Cluster 
Number 
of 
Census 
Tracts 
Relative 
Risk p-value 
P
er
io
d
 1
 
 (
2
0
0
5
-2
0
0
7
) 
1 98 3.47 <0.0001 1 96 4.99 <0.0001 1 13 17.69 0.001 
2 55 3.77 <0.0001 2 23 3.9 <0.0001 2 11 6.23 0.003 
3 25 5.31 <0.0001 3 5 9.46 0.0004 3 1 371.29 0.03 
4 24 5.22 0.001 4 26 2.95 0.0004 4 77 3.85 0.03 
5 4 30.04 0.003 5 9 1.29 0.0008     
6 1 67.2 0.04 6 9 6.75 0.003     
        7 4 7.92 0.02         
P
er
io
d
 2
 
 (
2
0
0
8
-2
0
1
0
) 
1 101 3.86 <0.0001 1 116 4.05 <0.0001 1 19 5.87 0.0002 
2 62 3.25 <0.0001 2 95 2.4 <0.0001 2 13 7.17 0.04 
3 4 18.93 0.0002 3 3 19.7 <0.0001     
4 4 11.22 0.002 4 3 12.36 <0.0001     
5 15 3.58 0.02 5 3 14.73 <0.0001     
6 21 3.52 0.04 6 19 3.74 0.0005   
  
  
7 12 5.75 0.04 7 18 4.96 0.002   
  
  
  
  
  8 4 18.28 0.007   
  
  
        9 3 18.07 0.04         
P
er
io
d
 3
  
(2
0
1
1
-2
0
1
3
) 
1 71 4.06 <0.0001 1 97 3.94 <0.0001 1 21 10.37 <0.0001 
2 61 2.99 0.001 2 56 2.88 0.003 2 120 4.65 0.0003 
3 22 5.32 0.005 3 4 29.22 0.004 3 1 184.66 0.003 
4 7 8.57 0.008 4 3 13.48 0.006 4 7 13.7 0.007 
5 23 4.23 0.008 5 10 7.82 0.02     
6 3 14.86 0.02             
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